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1 ABSTRACT 
The standard proteasome is the major ATP-dependent multi-catalytic protein complex that is 
important for the proteolytic processing of short-lived and regulatory proteins. It also 
degrades exogenous or improperly synthesized, misfolded, and damaged proteins. Cells of 
hematopoietic origin predominantly express an alternative variant - the immunoproteasome 
(IP), which is characterized by three specific catalytically active subunits (β1i/LMP2, 
β2i/MECL-1 and β5i/LMP7). In non-immune cells, these immunosubunits are also induced 
and incorporated into newly assembling IPs upon exposure to interferons. As compared to 
standard proteasomes, IPs display altered cleavage site preferences, resulting in the generation 
of a different spectrum of antigenic peptides for MHC class I presentation. Thus, IP-formation 
has long been linked to the optimization of the CD8+ T cell response to viral infections. 
However, contrary in vivo studies recently reported on sufficient virus-specific CD8+ T cell 
responses despite the lack of individual IP subunits, which suggests a more complex 
physiological role of IPs.  
The present thesis investigates the impact of β1i/LMP2- and β5i/LMP7 within the context of 
viral heart disease, making use of the well-established murine model of coxsackievirus B3 
(CVB3) infection. β5i/LMP7-deficient mice demonstrate a potent CD8+ T cell capacity to 
control CVB3 infection, resulting in viral clearance after the acute stage of disease. The 
expression of pro-inflammatory cytokines, innate antiviral mediators, and CVB3-specific IgG 
antibodies argue against a specific role of IPs in the induction of an effective immune 
response against CVB3 infection. However, the impaired incorporation of all three 
immunosubunits in β5i/LMP7-deficient hearts coincides with severe inflammation and 
myocardial tissue damage. Exposure to IFN-γ gives rise to prolonged accumulation of 
oxidant-damaged, poly-ubiquitylated proteins in IP-deficient cardiomyocytes and 
inflammatory cells. Along with the restricted degradation of toxic protein aggregates, 
inflammatory cells and the adjacent myocardium are prone to increased apoptotic cell death. 
By contrast, the deletion of β1i/LMP2 results in the formation of intermediate proteasomes 
containing both, β2i/MECL-1 and β5i/LMP7 subunits, and does not affect the phenotype of 
CVB3 myocarditis. 
Collectively, these findings point towards a pivotal role of IPs in the adaptation to oxidant 
protein damage. The formation of IPs preserves protein homeostasis and cell viability in the 
pro-inflammatory cytokine milieu of viral heart disease. 
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2 ZUSAMMENFASSUNG 
Das Proteasom ist ein multikatalytischer, ATP-abhängiger Enzymkomplex, der kurzlebige 
und regulatorische Proteine in der Zelle abbaut und somit verschiedene Prozesse wie die 
Signalübertragung oder Zelldifferenzierung beeinflusst. Im Rahmen der 
Proteinqualitätskontrolle werden durch das Proteasom auch fehlerhaft synthetisierte bzw. 
falsch gefaltete oder chemisch geschädigte Proteine degradiert. Zellen hämatopoetischen 
Ursprungs exprimieren sogenannte Immunoproteasomen (IP), die durch drei alternative 
katalytische Untereinheiten (β1i/LMP2, β2i/MECL-1 sowie β5i/LMP7) charakterisiert sind. 
Unter dem Einfluss von Interferonen kommt es auch in nicht-hämatopoetischen Zellen zur de 
novo Assemblierung von IP. Sie weisen im Vergleich zu Standardproteasomen einen erhöhten 
Substratumsatz sowie veränderte Schnittpräferenzen auf. Dadurch können Standard- und 
Immunoproteasomen verschiedene MHC (major histocompatibility complex) Klasse I-
restringierte antigene Peptide generieren. Vor allem in viralen Erkrankungen wurde die 
Expression von IP daher lange Zeit hauptsächlich mit einer effizienten Induktion der CD8+ T-
Zellantwort in Verbindung gebracht. Aktuelle Untersuchungen zeigen jedoch, dass die 
Expression von IP nicht in allen Modellen zur Optimierung der Antigenprozessierung führt. 
Dies lässt auf eine komplexe physiologische Funktion von IP neben der Epitopgenerierung 
schließen. Die vorliegende Arbeit untersucht die Relevanz der β1i/LMP2- bzw. der 
β5i/LMP7- Untereinheit im Rahmen der viralen Myokarditis. Hierfür stellt die murine CVB3 
(Coxsackievirus B3) Infektion ein gut charakterisiertes Modell dar.  
β5i/LMP7-defiziente Mäuse zeigen eine suffiziente CD8+ T Zell Antwort, die zur 
vollständigen Viruselimination nach der akuten Entzündungsphase beiträgt. Die reguläre 
Expression pro-inflammatorischer Zytokine und antiviraler Signalwege sowie CVB3-
spezifischer IgG-Antikörper spricht gegen eine spezielle Funktion von IP bei der Induktion 
einer effektiven Immunantwort in diesem Modell. Es konnte jedoch gezeigt werden, dass der 
verminderte Einbau aller IP-Untereinheiten in β5i/LMP7-defizienten Mäusen mit einer 
schweren Inflammation und Myokardschädigung einhergeht. Der verringerte Substratumsatz 
führt zur Akkumulation von polyubiquitinylierten, oxidativ geschädigten Proteinen sowie zur 
verstärkten Apoptose IP-defizienter Kardiomyozyten und inflammatorischer Zellen. Des 
Weiteren ist die Regulation NF-κB-abhängiger Signalwege durch die IP-Defizienz 
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beeinträchtigt. Die Deletion von β1i/LMP2 führt hingegen zur Expression sogenannter 
Mischproteasomen, in denen sowohl β2i/MECL-1 als auch β5i/LMP7 inkorporiert sind. Im 
Gegensatz zur IP-Defizienz in β5i/LMP7-/- Mäusen hat das Fehlen der β1i/LMP2 Untereinheit 
keinen Einfluss auf die Ausprägung der CVB3-Myokarditis. Zusammenfassend trägt diese 
Arbeit maßgeblich zum Verständnis der biologischen Relevanz von IP bei. Im 
proinflammatorischen Zytokinmilieu der akuten CVB3 Myokarditis erhalten IP die 
Proteinhomöostase und damit letztlich die zelluläre Funktionalität. 
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3 INTRODUCTION 
3.1 Myocarditis and dilated cardiomyopathy 
Myocarditis is defined as a cardiac disease associated with the inflammation of the 
myocardium and necrosis and (or) degeneration of adjacent myocytes in the absence of an 
ischemic event (1). Susceptibility to viral heart disease seems to be age related, as about 52% 
of myocarditis occur in children and young adults (2). The clinical manifestation of 
myocarditis is highly variable, ranging from asymptomatic courses or nonspecific signs (e.g. 
fever, myalgia) to acute heart failure and sudden death (1-3). Due to this vast diversity of 
clinical presentations, diagnosis is rather difficult. A combination of different magnetic 
resonance imaging methods represents the most useful noninvasive tool to diagnose 
myocarditis, but no information about the degree of inflammation or presence or type of 
causative agents can be obtained (4). Therefore, endomyocardial biopsy remains gold 
standard for the diagnosis of myocarditis (4;5). Following the Dallas criteria, the first 
endomyocardial biopsy is classified into acute (myocytolysis) and Borderline (no 
myocytolysis) myocarditis. Subsequent biopsies differentiate between persistent, resolving 
and resolved myocarditis (1;6;7). According to the WHO/ISFC Task Force, the myocardium 
is considered to be inflamed after immunohistochemical detection of focal or diffuse 
mononuclear infiltrates with >14 leukocytes per mm2 (CD3+ T lymphocytes and/or CD68+ 
macrophages) (8). Of note, the Dallas criteria are limited by interobserver variability and lack 
of prognostic value (5;9). 
Acute myocarditis can improve spontaneously in approximately 50% of patients, or it 
progresses to a chronic form, and may subsequently deteriorate to dilated cardiomyopathy 
(DCM) (10). DCM is characterized by ventricular dilatation with normal LV wall thickness 
and systolic dysfunction of the left or both ventricles (11). Arrhythmias, conduction system 
abnormalities, thromboembolism and sudden or progressive heart failure-related deaths are 
common and may occur at any stage of disease (8).  
Whereas acute myocarditis with preserved left ventricular ejection fraction or its 
normalization during short-term follow up is linked to high rates of spontaneous improvement 
(4;12), clinical presentation with heart failure is a predictor for incomplete long-term recovery 
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(4;13). Patients of the latter cohort more likely develop DCM or need heart transplantation 
(12). Progress to chronic dilated cardiomyopathy is correlated to a poor 5-year survival rate of 
less than 50% (3).  
Apart from idiopathic myocarditis where the causative agent is not known, major etiologies 
include viral, bacterial, protozoan or mycotic infections, gene mutations, autoimmune 
inflammation, and exposure to toxins (3;14).  
3.2 Coxsackievirus B3 
Coxsackieviruses are human-pathogenic enteroviruses within the family of picornaviridae. 
There exist two serogroups (A and B), both being primarily transmitted by the fecal-oral route 
or respiratory aerosols. Whereby Coxsackievirus A serotypes mainly cause enteric disorders, 
all known Coxsackie B viruses are associated with a broad range of severe diseases, including 
pancreatitis, aseptic meningitis, or type I diabetes mellitus (2;15;16). The serotype CVB3 has 
long been reported to be among the most frequent causes of viral myocarditis, especially in 
young infants (2). During the last years, the epidemiologic spectrum of most frequent viruses 
shifted from classic enteroviruses such as CVB3 and adenoviruses to parvovirus B19 and 
human herpes virus 6 (4;17;18). Nonetheless, the experimental model of murine CVB3 
myocarditis is well-established. Different resistant and susceptible mouse strains mimic the 
diverse human disease progression and allow a mechanistic investigation of host genetic 
factors. 
3.2.1 Structure and life cycle of CVB3 
CVB3 is a non-enveloped, icosahedral virus, encompassing a 7.4 kb positive sense, single-
stranded RNA genome ((+)ssRNA). After attachment of CVB3 to the decay-accelerating 
factor (DAF) on the apical cell surface, Rac-dependent actin rearrangement permits virus 
movement to tight junctions (19), where the coxsackievirus and adenovirus receptor (CAR) is 
located (20;21). Interaction of CVB3 with CAR promotes conformational alterations within 
the virus capsid, which are crucial for virus entry and RNA release (21). In the cytoplasm, the 
viral RNA serves as a template for the translation of a large polyprotein (Fig. 1). The genome 
of CVB3 does not contain a 7-methyl guanosine cap structure as it is found at the 5′ end of 
eukaryotic genomic RNAs. Instead, viral VPg protein is involved in the initiation of protein 
synthesis via a cap-independent mechanism that utilizes an internal ribosome entry site 
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(IRES) in its 5’ untranslated region (UTR) (22). Subsequently, the virus-encoded proteases 
2APro and 3Cpro cleave the synthesized polyprotein into three precursor molecules (P1, P2, and 
P3) (2;22). 3CDPro then cleaves P1 into structural capsid proteins (VP1 – VP4), while the P2 
and P3 segments will result in nonstructural viral proteases and polymerases (2Apro, 2B, 2C, 
3A, 3B/VPg, 3Cpro/3CDpro, 3Dpol). These processes occur since proteases (2A, 3C) are capable 
to fold into an active conformation and to auto-cleave during translation (2;22). In addition, 
several cellular proteins are cleaved by viral proteases, including the translation initiation 
factor eIF4G, thereby inhibiting cap-dependent host cell translation (23).  
 
Fig. 1 The CVB3 polyprotein and proposed functions of single components (based on Esfandiarei, 2008). 
Viral 3Dpol, an RNA-dependent RNA-polymerase, generates the protein primer VPg-pU-pU 
(VPg uridylation) to initiate negative-strand RNA synthesis at the 3’ poly(A) region of the 
viral genome (24). In turn, multiple copies of negative-sense RNA serve as templates for the 
production of positive-strand RNA genomes. These can either be packaged and released as 
progeny viruses, or they act as templates for subsequent rounds of cap-independent translation 
(2;22). From entry to the release of progeny virus, this lytic replication cycle occurs within 
approximately 6-8 h (25). 
3.2.2 Mechanisms of virus replication and inflammation in experimental 
CVB3-associated myocarditis 
The experimental model of murine CVB3 myocarditis allows the investigation of mechanisms 
that contribute to the onset and progression of human viral myocarditis. Resistant mouse 
strains (e.g. C57BL/6 or DBA/1J) are capable of eliminating the virus, leading to complete 
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recovery. By contrast, susceptible mice (e.g. A.BY/SnJ or A/J) develop chronic myocarditis, 
which is accompanied by virus persistence in the myocardium (2). Accordingly, the host’s 
genetic background and the nature of the immune response influence the pathophysiology of 
viral myoarditis. 
Following intraperitoneal injection, CVB3 replicates in the pancreas, spleen, heart, and brain 
(26). Concomitant with prominent virus replication, substantial necrotic and apoptotic 
cardiomyocyte death is observed during the viremic stage 3 to 4 days postinfection (2;27). 
Although no inflammatory processes take place in the myocardium at this time point, 
cytolytic CVB3 replication may cause a high mortality rate in certain susceptible mice 
(14;28). However, in most resistant as well as susceptible mice, the non-inflammatory phase 
is not immediately lethal, but followed by acute myocardits around day 8 postinfection 
(14;27). This is initialized by the injurious infection, which causes immunogenic cell debris 
and elevated myocardial expression of cytokines e.g. interleukin 1α and interleukin 6 (IL-1α, 
IL-6), tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ) up to day 5 postinfection 
(2;27). Thereby, the migration of natural killer-like cells that express cytolytic perforin is 
stimulated (29). The substantial increase of proinflammatory cytokines then triggers the 
second wave of immune cell infiltration, primarily consisting of CD4+ T helper cells and 
cytotoxic CD8+ T cells (27;30) as well as macrophages (30). These infiltrating cell types are 
found in human myocarditis and, by day 11 postinfection, also in the murine model of CVB3 
myocarditis (27;31;32).  
Multifactorial mechanisms participate in the transition from acute myocarditis to chronic 
manifestation and its late sequelae, dilated cardiomyopathy and heart failure (14;27). At the 
acute stage, the balance between viral clearing and healing in contrast to myocardial damage 
and exaggerated immune activation is crucial for the outcome of infection. For example, 
cytotoxic CD8+ T cells (CTLs) are required to limit CVB3 replication in the myocardium (33) 
however, the release of perforin by these CTLs causes severe myocardial fibrosis (34). 
Moreover, the development of chronic myocarditis can be triggered by persistent, Th-17 cell-
mediated IL-17 secretion, which induces a prolonged inflammatory environment and in turn 
facilitates the generation of autoreactive antibodies (27). In murine myocarditis, such 
autoantibodies e.g. against cardiac myosin heavy chain, desmin, and actin develop as early as 
day 7 postinfection (2;35) and can induce injury of both, infected and uninfected 
cardiomyocytes (2). Also, a highly reactive inflammatory environment can result from 
synergistic signaling by proinflammatory cytokines such as TNF-α and viral replication (27). 
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Actually required for pathogen defense, activation of NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells) by the PI3K/Akt (phosphatidylinositol 3-kinase/ protein 
kinase B) pathway is utilized by CVB3 for successful replication in infected cells (36). TNF-α 
was shown to enhance cell viability via the NF-κB pathway (36), thereby promoting provirus 
replication signals in infected cells (27). 
3.3 The Ubiquitin-Proteasome System 
In the heart, the high metabolic rate and mechanical work load, but also neurohumoral 
regulation and exposure to various cellular stressors represent a particular challenge to the 
ubiquitin-proteasome system (UPS) (37). The UPS is involved in the maintenance of cellular 
protein homeostasis, which is a very complex and precisely regulated process encompassing 
RNA metabolism and processing, protein synthesis and folding, protein 
assembly/disassembly, translocation, and degradation. The latter function is mainly carried 
out by the UPS. Proteins that are involved in various cellular processes such as signal 
transduction, transcription, cell-cycle control, differentiation, or apoptosis, are degraded by 
this ATP-dependent system (38;39). Aside from removing short-lived regulatory proteins, the 
UPS also degrades structurally aberrant proteins (40), which is particularly important in long-
lived, non-proliferating cells such as cardiomyocytes or neurons (41). Furthermore, the 
proteasome is involved in the efficient immunosurveillance of cellular and pathogenic 
translation products by the generation of specific peptides for MHC class I antigen 
presentation (38). The structural composition of proteasomes varies between different organs 
(42) and adapts to organ-specific requirements and pathophysiological conditions. In many 
cardiomyopathies, including diabetic cardiomyopathy (43), ischemia-reperfusion injury (44) 
and CVB3-associated myocarditis (45), the expression and activity of so-called 
immunoproteasomes (IPs) is significantly elevated. It has been reported that UPS dysfunction 
is a pathogenic factor for a large subset of cardiovascular disorders, such as pressure overload 
cardiac hypertrophy or ischemic heart disease (37). These diseases have been associated with 
oxidative modifications and/or downregulation of proteasome subunits, and decreased 
proteasome activity. Impaired proteasome function compromises protein quality control in 
heart muscle cells; determining the progression to chronic heart failure. However, 
pharmacological inhibition of proteasome activity was also shown to be a potential 
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therapeutic strategy, as it protects against cardiac remodeling e.g. in pressure-overload cardiac 
hypertrophy (37). 
3.3.1 Ubiquitylation and the standard 26S proteasome 
Throughout eukaryotes, ubiquitin (Ub) is a highly conserved small protein of 76-amino-acids, 
which regulates virtually all aspects of cellular protein metabolism. Posttranslational substrate 
modification by the conjugation of ubiquitin either marks a protein for degradation, or it 
changes its conformation, activity, stability, or location (46;47). Catalyzed by an enzymatic 
cascade - the ubiquitylation, ubiquitin is activated, transferred, and covalently attached to 
lysine residues of target proteins. The activating enzyme E1 uses ATP to adenylate ubiquitin 
at its C terminus, resulting in the formation of a thioester bond between the sulfhydryl group 
of the E1 active-site cysteine and the glycine residue of ubiquitin while expelling AMP. 
Second, activated ubiquitin is passed to the active-site cysteine of an E2 family member 
(conjugation). The Ub-E2 complex is finally recruited to an E3 ligase which specifically binds 
the C terminus of Ub to the ɛ-amino group of a lysine in the substrate by an isopeptide linkage 
(ligation) (47-49). Ubiqitylation is a dynamic and reversible process of protein modification. 
De-ubiquitylating enzymes (DUBs), that are also important for C-terminal processing of 
immature ubiquitin prior to ubiquitylation (47), cleave Ub from proteins and residual 
proteasome-associated peptides. Furthermore, DUBs recycle ubiquitin by the disassembly of 
multi-Ub chains (50).  
Whether a protein is degraded or otherwise modified depends on the structure of the Ub chain 
that is transferred to the target protein. Monoubiquitylation is the attachment of a single Ub to 
a protein, and is involved e.g. in targeting cell-surface proteins for internalization and 
subsequent lysosomal degradation (51). Multiubiquitylation describes the tagging of multiple 
lysine residues of the target protein with single Ub molecules. Polyubiquitylation occurs, 
when ubiquitin itself is modified at one of its seven internal lysine residues (52;53). While 
chain linkage through the lysine residue at position 63 of ubiquitin (Lys-63) is reported to be 
involved in numerous non-proteolytic processes e.g. DNA damage tolerance, Lys-48-linked 
polyubiquitin chains mostly target substrates for degradation by 26S proteasomes (46;54). 
The 26S proteasome is a large protein complex, consisting of the catalytically active 20S core 
and a 19S regulatory particle that recognizes and unfolds Ub-tagged proteins (Fig. 2A). Axial 
stacking of four heteroheptameric rings - two outer α- and two inner β-rings forms the 
cylindrical 20S core. 
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Fig. 2 Ubiquitylation, the 26S proteasome and formation of immunoproteasomes. A: ATP-dependent 
substrat ubiquitylation is mediated by E1 activating, E2 conjugating, and E3 ligating enzymes. For degradation, 
ubiquitylated proteins are directed to the 26S proteasome, which consists of the catalytic 20S core and 19S 
regulatory proteins. Upon CVB3 infection/cytokine induction, the immunosubunits β1i/LMP2, β2i/MECL-1 and 
β5i/LMP7 are incorporated into the 20S core via de novo synthesis. B: Molecular model of the 26S proteasome 
subunits and their function (modified from da Fonseca et al. (55) and Saeki et al. (56). 
Each ring comprises seven structurally similar α- and β-subunits (α1-7; β1-7). Only the β1, 
β2 and β5 subunits contain catalytically active sites for the cleavage of peptide bonds at the 
carboxyl side of acidic, basic and hydrophobic amino-acid residues, respectively. These 
specific cleavage preferences are referred to as caspase-, trypsin- and chymotrypsin-like 
activities (57-59). The outer α-subunits form a channel through which substrates enter the 
catalytic 20S core protein (CP). The N-terminal tails of these α-subunits function as a gate 
and restrict unregulated protein degradation (60;61) (Fig. 2B). Gate opening is mediated e.g. 
by 19S regulatory proteins (RP) (62), which comprise two subcomplexes, namely the lid and 
the base. Both subcomplexes consist of different subunits that are classified into regulatory 
particle of triple-ATPases (Rpt) or regulatory particle of non-ATPases (Rpn) (59).  
The base is constituted of four non-ATPase subunits (Rpn1, 2, 10 and 13) and six 
homologous AAA-ATPases (Rpt1-6) (59). Rpn10 and Rpn13 function as integral ubiquitin 
receptors and trap polyubiquitylated substrate proteins via a C-terminal ubiquitin-interacting 
motif (Rpn10) or a N-terminal “pleckstrin-like receptor for ubiquitin domain” (Rpn13) 
(55;59). The ATPase subunits promote gate opening as well as substrate unfolding before 
translocation of target proteins into the 20S cavity (58;59). The lid subcomplex, which is 
composed of at least nine non-ATPase subunits (Rpn3, Rpn 5, Rpn6, Rpn 7, Rpn 8, Rpn 9, 
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Rpn 11, Rpn 12 and Rpn 15), deubiquitylates captured substrates, whereby the 
metalloisopeptidase Rpn11 plays the major role (55;58) (Fig. 2B). The 19S complex can dock 
at either one or both sides to the 20S core, thus forming 26S and 30S proteasomes, 
respectively. However, both isoforms are mostly described as 26S proteasomes (59). 
3.3.2 IFN-γ-inducible subunits: Immunoproteasomes and PA28 
Immune cells and tissues constitutively express three alternative catalytic β-subunits: 
β1i/LMP2, β2i/MECL-1, and β5i/LMP7 (63). Both, β1i/LMP2 and β5i/LMP7 are encoded 
within the major histocompatibility complex class II region (MHCII) on chromosome 6 (64), 
whereas β2i/MECL-1 is localized in a cluster of unrelated genes on chromosome 16 (65). 
Similar to the majority of proteins that are related to the MHC antigen presentation pathway, 
expression of these proteasomal “immunosubunits” can be induced in non-lymphoid cells 
upon cytokine stimulation, particularly by IFN-γ (Fig. 2) (66;67). β1i/LMP2, β2i/MECL-1, 
and β5i/LMP7 substitute their homologous standard counterparts (β1, β2 and β5, respectively) 
by cooperative assembly into nascent 20S cores (38;66). Whether standard or 
immunosubunits are incorporated into de novo synthesized proteasomes depends on specific 
interactions between the subunits and the post-transcriptional downregulation of standard β-
subunits (68-70). The proteasome maturation protein (POMP), which is also induced by IFN-
γ, determines the recruitment of β5i/LMP7. The accelerated degradation of POMP is directly 
linked to the fast maturation of β5i/LMP7 upon IFN-γ stimulation (70). Consequently, 
β5i/LMP7 is incorporated preferentially over β5 into pre-proteasomes containing β1i/LMP2 
and β2i/MECL-1, whereby β2i/MECL-1 requires β1i/LMP2 for efficient incorporation into 
these pre-proteasomes (69-71). Mature immunoproteasomes (IPs) are characterized by an 
altered catalytic profile compared to their standard counterparts. In vitro, β5i/LMP7 increases 
the capacity to cleave after basic and hydrophobic amino acid residues (referred to as trypsin- 
and chymotrypsin-like activity), whereas the incorporation of β1i/LMP2 reduces the cleavage 
after acidic residues (=decreased caspase-like activity) (72;73). These differential proteolytic 
activities contribute to the diversification of the antigenic peptide repertoire for MHC class I 
presentation (74).  
IFN-γ also induces the expression of the proteasome activator PA28/11S, which belongs to 
the family of 20S proteasome regulators. PA28 is composed of two homologous subunits, 
PA28α and PA28β, that assemble into a heteroheptamer (α3β4) (75-77). PA28 binds to the 
20S proteasome in an ATP-independent way, thus facilitating α-ring opening. It can attach to 
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both sides of the 20S core [PA28-20S-PA28] or it is found in complexes that also contain a 
19S regulator, thus forming so called hybrid proteasomes [19S-20S-PA28] (78). Formation of 
PA28-20S-PA28 complexes activates cleavage of peptides but not of intact native or 
ubiquitinylated proteins (75;79). Kinetic studies demonstrated, that binding of PA28 to 20S 
cores does not affect the maximal activity of the enzyme complex, but that it increases 
substrate affinity and enhances either the uptake or release of products (80;81). 
3.3.3 Antigen processing by standard and immunoproteasomes 
Antigen presentation constitutively occurs in almost all nucleated cell types of vertebrates as a 
side product of normal protein turnover. The main source for major histocompatibility 
complex (MHC) class I presentation are endogenous, pathogenic or tumor-associated proteins 
that are primarily degraded by the proteasome (82). Oligopeptides that are generated by 
proteasomes are either of the correct size or subsequently trimmed on their N-termini by 
aminopeptidases in the cytosol and the endoplasmatic reticulum (ER) (83). Translocation into 
the endoplasmatic reticulum (ER) is mediated by transporters associated with antigen 
processing (TAPs) (84). In the ER, peptides of 8-9 amino acid residues are loaded onto MHC 
class I dimers. MHC class I molecules are heterodimers, consisting of a heavy chain folding 
into three domains (α1, α2 and α3) and β2-microglobulin. The α1 and α2 domains form the 
peptide-binding groove on the upper surface of the MHC class I molecule (85). Antigenic 
peptides stabilize the MHC complex; otherwise its stability is mediated by ER-associated 
chaperone proteins such as calreticulin, ERp57, and tapasin. Tapasin, which is directly linked 
to TAPs, couples peptide transportation into the ER and peptide binding to nascent MHC 
class I molecules (82). Peptide-loaded MHC class I molecules are released from the 
chaperones and transported to the cell surface via the Golgi complex, finally resulting in the 
presentation of high-affinity complexes to CD8+ CTLs (82;85) (see Fig. 3). MHC class I 
molecules, which are unable to assemble correctly, are translocated to the cytosol by the ER-
associated protein degradation (ERAD) system and ultimately degraded by proteasomes (86).  
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Fig. 3 Generation and presentation of MHC class I antigens. The proteasome degrades timely regulated 
cytosolic and nuclear proteins, but also structurally aberrant or pathogenic proteins. Generated peptides are 
actively transported into the lumen of the endoplasmatic reticulum (ER) by transporters for antigen processing 
(TAPs). Several chaperones like tapasin, calreticulin, calnexin, and ERp57 facilitate peptide binding to MHC 
class I molecules. Loaded MHC class I complexes are released into the Golgi, transported to the cell surface, 
and presented to CD8+ cytotoxic T cells. Due to T cell maturation, T cell receptors (TCRs) can discriminate 
between “self” and “non-self” antigens (87) (modified from Neefjes et al., 2011 (82)).  
 
A large fraction of peptide ligands for MHC class I complexes arises from nascent proteins 
that are degraded and presented shortly after synthesis (88) (see Fig. 3). These so called 
defective ribosomal products (DRiP hypothesis) consist of prematurely terminated and 
misfolded polypeptides that can result from defective transcription or translation, ribosomal 
frame shifting, oxidative stress or virus associated alterations of the cellular translation 
machinery (82;88-91). Thus, the DRiPs hypothesis explains the prompt MHC class I 
presentation of viral antigens within 1.5 hours post-infection despite the relatively long half-
life of most viral proteins, as demonstrated for Influenza A neuraminidase (92). 
In contrast to standard proteasomes, which are located throughout the cytoplasm and nucleus, 
IPs are enriched at the ER (93). In fact, IPs and PA28 are directly associated with MHC class 
I-TAP complexes on the ER by physical interaction (94). The enrichment of IPs at the ER 
may mediate the efficient transport of IP-generated peptides into the lumen of the ER as 
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compared SPs (93). Many studies show that IPs favor the generation of peptides with C-
terminal hydrophobic or basic residues while suppressing cleavages after acidic residues in 
vitro (66;95;96). Peptides with C-terminal hydrophobic and basic residues preferentially bind 
to TAP transporters and MHC class I molecules (83). However, processing of larger 
polypeptides and protein substrates demonstrated that different catalytic subunits are able to 
cleave after the same residues (97).  
In an experimental infection model, HeLa cells were infected with vaccinia virus expressing 
the hepatitis B virus core antigen. Stimulation of HeLa cells with IFN-γ and thus expression 
of IPs was required for the efficient liberation and presentation of the hepatitis B epitope 
(HBVcAg141-151) (98;99). Sijts et al. found that the incorporation of a functional β5i/LMP7 
subunit and of an inactive β5i/LMP7 T1A mutant both led to the generation of the CTL 
epitope (98). Thus, an altered cleavage profile must not necessarily be caused by the cleavage 
specificity, but rather by structural changes on the proteasome complex due to the presence of 
immunosubunits (98). However, mass spectrometrical analysis revealed that not only IPs, but 
also SPs were able to generate low levels of HBVcAg141-151. Strehl et al. discuss, that IPs 
more likely influence the available amount and therefore the quantity of a given epitope, and 
that an immunological effects only becomes detectable once a quantitative threshold is 
reached (99). The specific effect of IP-expression on the CD8+ T cell repertoire seems to 
depend on the underlying model: while β1i/LMP2- and β5i/LMP7-deficient mice mount 
strong lymphocytic choriomeningitis virus-specific CD8+ T cell responses (100), the 
immunodominance hierarchy of CD8+ T cell responses is altered in response to influenza 
virus infection in β1i/LMP2-deficient mice (101). 
3.4 Proteostasis 
In eukaryotes, protein folding is a highly complex mechanism and misfolded proteins need to 
be distinguished from those that obtain their native conformation. The balance between 
protein translation, folding and degradation by the proteasome is sensitive to regular 
development and aging. Cellular stressors such as viruses additionally challenge proteostasis, 
as they require enhanced protein folding and trafficking capacity for viral replication and 
assembly (102).  
To maintain the protein equilibrium, there exists the inducible heat shock response (HSR) 
pathway that regulates the adaptation of the cytoplasmatic proteostasis (102). The HSR is 
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orchestrated by heat shock factor 1 (Hsf1) (103;104). Upon protein-damaging stress 
conditions, activated heat shock transcription factors bind to promoter elements upstream of 
heat shock inducible genes via a N-terminal DNA binding domain, thereby initiating their 
enhanced transcription (103). Heat shock proteins promote refolding of misfolded proteins 
and prevent protein aggregation (103).  
Furthermore, two types of protein quality control - the endoplasmic-reticulum-associated 
degradation (ERAD) and the unfolded protein response (UPR) - are responsible for the 
recognition and degradation of conformationally aberrant and toxic proteins of the exocytic 
pathway (105). The UPR is controlled by three ER-bound proteins: the activating 
transcription factor 6 (ATF6), the type I transmembrane protein kinase and endoribonuclease 
(IRE1), and the RNA-activated protein kinase-like ER kinase (PERK) (106;107). Upon 
activation, ATF6 is relocalized from the ER to the Golgi apparatus where it is cleaved to a 
nuclear transcriptation factor that activates stress-responsive genes. Turnover of ATF6 is 
regulated by the ubiquitin-proteasome system (108). PERK, like IRE1, contains a luminal 
domain that detects misfolded proteins. Activation of PERK results in the generalized 
inhibition of protein synthesis (104). IRE1 kinase activation leads to splicing of the 
transcription factor XBP1 (X-box binding protein 1), which removes a translational inhibitory 
region. The protein product then activates the transcription of genes that are required for 
protein folding, ER growth, ER-to-Golgi trafficking, and the ER-associated degradation 
system ERAD (104;106) (see Fig. 4).  
If the correct protein conformation cannot be achieved, proteins are eventually degraded by 
the ERAD. There are at least two distinct ERAD mechanims – ERAD-L for misfolded 
lumenal (soluble or membrane-tethered) domains and ERAD-C, which detects cytosolic 
domains of transmembrane proteins (104). Aberrant proteins of both pathways are 
ubiquitylated, retrotranslocated to the cytosol and degraded by proteasomes (106). The central 
player of all ERAD pathways are multi-protein transmembrane complexes formed around E3 
ubiquitin ligases. One of the best characterized class of eukaryotic E3s are the HRD (3-
hydroxy 3-methylgutaryl coenzyme A reductase degradation protein) ligases (109). Adaptor 
proteins such as the mammalian SEL1L (protein sel-1 homolog 1) are peripheral components 
of the E3 complex, that contain a transmembrane domain and a large luminal domain 
composed of multiple tetratricopeptide repeats that facilitate protein-protein interactions 
(109;110). SEL1L recognizes ERAD substrates and recruits them to the side of dislocation, as 
it binds to HRD1 (111). Translocation across the ER membrane is driven by the cytosolic 
AAA ATPase p97/VCP (valosine-containing protein) (109;112).  
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In contrast to the UPR, which regulates the secretory pathway, the HSR is predominantly a 
mechanism to cope with cytosolic stress conditions. However, the HSR is also activated by 
ER-stress and enhances the ER export of misfolded proteins if the UPR is unable to cope with 
the accumulation of abberent proteins (105). 
3.4.1 Aggresome-like induced structures 
Upon various stress conditions including infection, inflammation and oxidative stress, 
polyubiquitylated proteins can also be transiently stored in cytosolic aggresome-like induced 
structures (ALIS) (113). ALIS formation and maintenance is dependent on protein synthesis, 
indicating that most of the proteins are newly synthesized proteins respectively DRiPs 
(113;114). A recent study by Liu et al. demonstrated that ALIS formation requires the 
polyubiquitin-binding protein p62 (nucleoporin 62; also called sequestosome-1), NF-κB, and 
the activation of the mTOR (mammalian target of rapamycin) pathway. ALIS are storage 
compartments that efficiently sequester aggregating proteins from the remaining cellular 
protein pool, representing a cytosolic unfolded protein response. Notably, p62-mediated ALIS 
formation is sensitive to ER stress. Cells that lack the IRE1-XBP1 branch of the classic UPR 
show exaggerated up-regulation of p62 levels, suggesting cross talk between the UPR in the 
ER and cytosolic ALIS formation (Fig. 4).  
 
Fig. 4 ALIS formation in response to inflammation and ER stress. mTOR signaling is induced by pathogen-
associated TLR activation and/or inflammation. Activation of mTOR is involved in protein synthesis and is 
unavoidably linked to an increased level of unfolded proteins in the cytosol. The UPR in the ER is also activated 
upon inflammation in order to reduce protein translation, and to increase protein refolding and degradation. As 
an adaptive physiologic mechanism, p62 recruits unfolded proteins in the cytosol to form ALIS. NF-κB is 
required for p62 mRNA transcription, whereby p62 is important for sustained NF-κB activation (adapted from 
Liu et al. (115)). 
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Clearance of ALIS is independent from autophagy and might be a combination of protein 
refolding and translocation as well as degradation by the proteasome (115). ALIS were also 
described in dendritic cells during lipopolysaccharide (LPS)-induced maturation, thus 
specified as dendritic cell aggresome-like induced structures (DALIS) (116). Lelouard et al. 
demonstrated, that selection and inclusion of DRiPs into DALIS is a well-organized process 
and that DRiPs are initially protected from proteasome degradation. The capacity to extend 
the half-life of aberrant proteins is likely to influence the MHC class I presentation in 
maturing DCs. Ubiquitylated DRiPs are stored in DALIS until the proteasome-mediated 
degradation is initiated, whereby proteasome inhibition increases the accumulation of 
DRiPs/DALIS at a later stage of DC maturation (114).  
3.5 Aims of this study 
The substantial impact of the UPS on cell physiology is predictive for consequences of UPS 
dysfunction. There is a growing body of evidence that several cardiovascular diseases are 
associated with defects in this degradation system (117). However, no conclusive studies 
about the implication of the UPS in viral heart disease have been performed to date. 
As an essential component of immune surveillance, the proteasome generates peptides from 
intracellular or pathogenic proteins, which are presented at the cell surface by MHC class I 
molecules. IPs have long been linked to the optimization of antigen presentation upon 
inflammation and viral infections. In mice being susceptible to coxsackievirus B3 
myocarditis, the formation of IPs as well as the liberation of virus-specific epitopes is delayed 
(118). These findings suggest disease-modifying effects of IP-formation in viral heart disease, 
qualifying this model for further investigation. Therefore, this thesis aims to examine the 
impact of β1i/LMP2- as well as β5i/LMP7-deficiency on cellular function and the induction 
of an effective CD8+ T cell response in murine CVB3-induced myocarditis. 
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4.1 Mouse experiments 
4.1.1 Mice 
strain source of supply 
C57BL/6 (J) wildtype initially from Jackson Laboratory, FEM Unit 3 
B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) Jackson Laboratory 
C57BL/6 β5i/LMP7-/- (background: C57BL/6 (J) 
N6) 
Ulrich Steinhoff (MPI for Infection Biology, 
Berlin)/ Hans Jörg Fehling 
C57BL/6 β1i/LMP2-/- (for background 
information see 5.3.2) 
Hansjoerg Schild (Institute for Immunology, 
Mainz)/ Luc van Kaer 
 
Mice were kept at the animal facilities of the Charité University Medical Center according to 
the European and Berlin State guidelines for animal welfare. The protocol was approved by 
the Committee on the Ethics of Animal Experiments of Berlin State authorities (Permit 
Numbers: G0311/06, H0204/08, H0076/08). Unless otherwise specified, all analyzed groups 
contained similar numbers of both, female and male animals. Background analysis was 
performed by a mouse 384 SNP panel at the Charles River Laboratories. 
4.1.2 Virus infection and organ preparation 
Four to six week-old mice were infected i.p. with 1x105 PFU Coxsackievirus B3 (Nancy 
strain, from Prof. Karin Klingel, Tuebingen (119), diluted in 100 µl sterile PBS. Control mice 
were sham treated with 100 µl PBS. Mice were sacrificed at indicated time points using 
Isofluran. Hearts were perfused with PBS and weighted; all organs were quickly frozen in 
liquid nitrogen before storage at -80°C. Parts of organs were fixed in 4% Roti® Histofix for 
paraffin embedding or were cryo-conserved with Tissue-Tek. Serum clotted for at least 
30 min at room temperature and was then centrifuged at 1100 rpm for 10 min. Supernatant 
was stored at -80°C. 
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4.1.3 CD8+ T cell transfer 
C57BL/6, β1i/LMP2-/-, β5i/LMP7-/- mice (CD45.2) and B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) 
mice were infected with 1x105 PFU CVB3 as described above. At day 8 post infectionem, 
mice were sacrificed and a single cell suspension of splenocytes was prepared as described in 
section 4.3.4. Following lysis of erythrocytes, cells were counted and CD8+ cells were 
selected using magnetic activated cell sort (MACS) as described in section 4.3.5. An aliquot 
of each sample was taken before and after CD8+ selection and analyzed by flow cytometry to 
verify the purity of isolated CD8+ cells. The isolated cells were diluted in 150 µl sterile PBS 
and injected i.v. into the tail vein. 1-2x106 cells yielded from one donor mouse were injected 
into one recipient mouse. Immediately after the transfer, recipient mice were infected with 
CVB3 as described above and sacrificed 8 days later. Again, splenocytes were isolated and 
analyzed by flow cytometry to determine the percentage of donor T cells by CD45.1- 
respectively CD45.2-specific antibody stainings. Myocarditis scores of recipient mice were 
determined as described above.  
4.1.4 Hemodynamic measurements 
Microconductance catheter measurments were realized by Dr. Konstantinos Savvatis (Berlin) 
as previously described (120). On account of different numbers of male animals between the 
investigated strains, only female animals were analyzed. 
4.2 Histological stainings 
4.2.1 In situ hybridization and HE-staining 
In situ hybridization of genomic CVB3 RNA and histological staining with hematoxylin-
eosin (HE) and were carried out by Prof. Karin Klingel (Tübingen) (30). To quantify 
myocardial damage comprising cardiac cell necrosis, inflammation, and scarring, a 
myocarditis score from 0 to 4 was applied (0: no inflammatory infiltrates, 1: small foci of 
inflammatory cells between myocytes, 2: larger foci of >100 inflammatory cells, 3: ≤ 10% of 
cross-section involved, 4: 10 to 30% of a cross-section involved) (121). 
Immunohistochemistry for detection of CD3+ T lymphocytes and Mac-3+ macrophages were 
carried out by Prof. Karin Klingel and analyzed as described (122). Staining for B cells was 
carried out by Dr. Stefan Prokop/Prof. Frank Heppner (Berlin) on a Ventana Benchmark 
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stainer using the Vectostain Elite ABC Kits (Vector Laboratories) using CD45R/B220 1:100 
(BD Pharmingen) and a biotin-labeled secondary antibody 1:100 (Dianova). 
4.2.2 Ubiquitin-staining 
Immunofluorescence: 6 µm cryosections were fixed in 4% paraformaldehyde for 3 min, 
washed in washing buffer for 5 min, permeabilized in 1% Triton X-100 for 10 min and 
blocked in blocking buffer for 1h. These steps were performed at room temperature while 
gently shaking. Monoclonal antibody FK1 (BIOMOL/Enzo Life Science) was added to each 
section 1:100 in staining buffer and incubated at 4°C overnight while gently shaking. After 
washing three times for 10 min, 200 rpm, secondary antibody was incubated 1:1000 at room 
temperature. Secondary antibody (anti-mouse IgG Alexa 488, Invitrogen) was co-stained with 
1:3000 DAPI. Subsequently, sections were washed three times for 10 min and rinsed once 
with distilled water. All buffers were filter-sterilized. Finally, sections were mounted with 
immumount and confocal images were acquired on a Leica TCS SP2 microscope (Leica 
Microsystems) with the help of Dr. Annett Koch. ALIS were quantified by counting poly-ub 
conjugates (focused staining over background defined as ub-rich inclusions) in defined areas 
(1088 µm2) at 200-fold magnification. 
washing buffer  
0.1% Triton X-100 in sterile PBS  
blocking buffer  
500 µl goat serum  
50 µl BSA  
40 µl 20% Triton X-100  
ad 10 ml sterile PBS  
staining buffer  
500 µl goat serum  
40 µl 20% Triton X-100  
ad 10 ml sterile PBS  
permeabilization buffer  
1% Triton X-100 in sterile PBS  
 
Immuohistochemistry: Paraffin embedded tissues were deparaffinized according to the 
protocol specified below. Ub-staining was performed by Dr. Stefan Prokop on a Ventana 
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Benchmark stainer using the Vectostain Elite ABC Kits (Vector Laboratories; Burlingame). 
Anti-ubiquitin antibody 1:1000 (DAKO Cytomation) and biotin-labeled secondary antibodies 
(Dianova) at a dilution of 1:100 were used. All slides were counterstained with hematoxylin 
and mounted with Eukitt after passing the sections through a series of increasing alcohol 
concentrations.  
deparaffinization  mounting   
xylene I  5 min ethanol 80% I rinse 
xylene II  15 min ethanol 80% II rinse 
ethanol absolut I  3 min ethanol absolut I 2 min 
ethanol absolut II  3 min xylene  5 min 
ethanol 95% I  3 min Eukitt  
ethanol 95% II  3 min   
ethanol 70% I  3 min   
ethanol 70% II  3 min   
distilled H20  3 min   
distilled H20  rinse   
4.2.3 TUNEL-assay 
DNA strand breaks (TUNEL assay) were determined by in situ cell death detection kit, TMR 
red (Roche) or in situ cell death detection kit, POD (Roche) according to the manufacturer’s 
instructions. In brief, paraffin embedded heart sections were deparaffinized and permeabilized 
for 8 min at room temperature. After rinsing sections with PBS twice, one section 
representing the positive control was pretreated with 1000 U/ml DNAse at room temperature 
for 10 min and rinsed with PBS three times. During this time, all other sections were covered 
with PBS. Then, 50 µl TUNEL reaction mix was added to each section and incubated for 
60 min at 37°C in a humified atmosphere in the dark. After washing with PBS for 10 min 
twice, sections were incubated with DAPI diluted 1:1000 in PBS for 10 min at room 
temperature. Sections were rinsed with PBS three times and mounted with Eukitt after passing 
through a series of increasing alcohol concentrations (see 4.2.2). For TUNEL-POD staining, 
50 µl converter solution were added to the sections after the TUNEL reaction. After rinsing 
three times, converter was incubated at 37°C for 30 min. Sections were rinsed in PBS three 
times and 50 µl DAB substrate was applied for 10 min at room temperature. Endogenous 
 21 
MATERIALS AND METHODS 
POD was blocked by immersing sections for 10 min in 3% H2O2 in methanol prior to cell 
permeabilization. 
By contrast, cryosections were fixed in 4% PFA/PBS, washed with PBS for 3 min twice, and 
permeabilization buffer was incubated for 2 min on ice. The positive control was pretreated 
with 3 U/ml DNAse. TUNEL assay was performed as described above. After final washing, 
sections were directly mounted with Immumount.  
permeabilization buffer  
0.1% Triton X-100 
0.1% sodium citrate 
in PBS 
 
4.3 Cell culture experiments 
4.3.1 Cells 
All cell culture experiments were performed under sterile conditions. Cells were incubated at 
37°C, 5% CO2. 
cell line characteristics source of supply 
HeLa human epithelial carcinoma cell 
line  
lab stock 
MEF murine embryonal fibroblast primarily isolated, E13/E14 
cardiomyocytes murine embryonal cells primarily isolated, E13/E14 
Vero C1008 kidney epithelial cells from African 
green monkey 
ATCC 
splenocytes murine splenoctes, B cell depleted primarily isolated 
4.3.2 Cell culture media 
medium for medium and supplements source of supply 
primary cardiomyocytes DMEM F0435, 4.5g glucose 
10 U/ml penicillin/streptomycin  
10% fetal calf serum  
Biochrom 
Biochrom 
Biochrom 
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medium for medium and supplements source of supply 
Vero MEM Eagle  
10% fetal calf serum  
2 mM L-Glutamin  
0.5 mg/ml Gentamycin  
Lonza 
Biochrom 
Biochrom 
PAA Laboratories 
MEF DMEM, 1g glucose 
10 U/ml penicillin/streptomycin  
10% fetal calf serum 
2 mM L-Glutamin  
 
Biochrom 
Biochrom 
Biochrom 
B cell depleted splenocytes RPMI + L-Glutamin 
10 U/ml penicillin/streptomycin  
10% fetal calf serum 
 
Biochrom 
Biochrom 
4.3.3 Isolation and infection of primary cardiomyocytes 
Pre-cooled solutions and organs were hold on ice during preparation. Embryos were separated 
at embryonic day 13 (E13). Uterus horns were placed in PBS; embryos were separated from 
the embryonic envelopes. The thorax was opened with fine forceps; the heart was isolated and 
incubated in 50 µl Trypsin/EDTA (PAA Laboratories) at 4°C over night. Following 
incubation at 37°C, 400 rpm for 15 min, cardiomyocytes were carefully resuspended in 1 ml 
pre-warmed medium and seeded in uncoated 12 well plates. Cells were cultured up to 7 days 
prior to experiments; the medium was changed every 3rd day. For immunoproteasome 
induction, cells were stimulated with IFN-γ (100 U/ml, PBL Biomedical Laboratories) 16h 
prior to infection.  
Cardiomyocytes were infected with CVB3 at MOI 0.1, 0.5 or 1.0 (Nancy strain, stock: 2x108, 
MOI  ) in complete medium for 1h. The supernatant was removed, complete 
medium was added and cells were cultured up to 24 h. 
4.3.4 Isolation of splenocytes 
Spleens were isolated from non-infected or CVB3-infected mice. During the following steps, 
cells were kept on ice. A single cell suspension was prepared by gently pressing the cells 
through a 70 µm nylon filter. Cells were washed with PBS and centrifuged for 5 min at 
1200 rpm, 4°C. The pellet was resuspended in 1 ml erythrocyte lysis buffer, incubated at 
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room temperature for 3 min and washed with 10 ml PBS twice. After centrifugation, the pellet 
was prepared for FACS analysis or MACS separation.  
erythrocyte lysis buffer   
10 mM KHCO3   
155 mM NH4Cl   
0.1 mM EDTA   
in dist. H20   
FACS buffer   
1% bovine serum albumin   
0.01% NaN3   
in PBS   
4.3.5 MACS separation 
A single cell suspension of splenocytes was prepared (see 4.3.4). Total splenocytes were 
counted and CD8+ T cells respectively B cell were separated using magnetic activated cell 
sort (MACS) according to the manufacturer’s protocol (Miltenyi Biotec). In brief, cells were 
resuspended in 90 µl of MACS buffer per 107 cells and incubated with 10 µl of CD8a (Ly-2) 
or CD45R (B220) microbeads (Miltenyi Biotec) for 15 min at 4°C. Cells were washed twice 
with MACS buffer, resuspended in 500 µl per 108 cells and separated on MS (CD8a) 
repectively LD (CD45R) columns (Miltenyi Biotec). An aliquot of each sample was taken 
before and after cell selection and analyzed by flow cytometry to determine the purity of 
isolated cells. 
B cell depletion kit source of supply 
CD45R (B220) mouse Miltenyi Biotec 
CD8+ T cell selection kit  
CD8a (Ly-2) mouse Miltenyi Biotec 
MACS buffer  
0.5% BSA  
2 mM EDTA   
in PBS  
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4.3.6 Pentamer staining 
Spleens and lymph nodes were isolated from single CVB3-infected animals at d8 p.i. and 
single cell suspensions were prepared (see section 4.3.4). Pentamer staining was performed as 
previously reported (118). In brief, CD8+ T cells were separated by MACS (see 2.3.5). MACS 
columns were washed with pentamer buffer to obtain the CD8+ positive cell fraction. 1.5x106 
cells were labeled with 10 µl H-2b-phycoerythrin (PE) pentamers for virus capsid protein 2 
(VP2) [285-293] (ProImmune) and incubated at room temperature for 15 min, shielded from 
light. Cells were washed and stained with anti-CD8-FITC and anti-CD19-PE/Cy5 antibodies 
at a dilution of 1:100 for 20 min. After washing, cells were fixed and fluorescence-activated 
cell sorting-analysis was performed on a FACSCalibur (BD, Germany). CD19-positive B 
cells were excluded from the analysis. 
pentamer washing buffer    
0.1% sodium azide 
0.1% BSA  
in PBS 
   
fix solution    
1% fetal calf serum 
2.5% formaldehyde  
in PBS 
   
4.3.7 FACS analysis 
Splenocytes were resuspended in 1 ml FACS buffer (1% BSA in PBS) and aliquoted for 
staining. Antibodies (see below) were diluted 1:100 in FACS buffer and cells were incubated 
with appropriate antibodies for 45 min on ice in the dark. Cells were washed twice with 
FACS buffer and were then resuspended in FACS buffer containing 2% paraformaldehyde for 
fixation (at least 15 min). For intracellular staining, cells were prepared in saponin buffer 
(0.5% saponin, 1% BSA, 0.01% sodium azide in PBS). The fluorescence intensity was 
measured on a Beckman Coulter Cyan ADP or BD FACSCalibur (Becton Dickinson) using 
the Summit v4.3 software. 
surface marker fluorescent dye source of supply 
CD3 PE  BD Pharmingen 
CD4 PerCP-Cy5.5 BD Pharmingen 
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surface marker fluorescent dye source of supply 
CD8 PB  BD Pharmingen 
CD19 FITC  BD Pharmingen 
B220/CD45R PE Miltenyi Biotech 
CD45.1 PerCp-Cy5.5 BD Pharmingen 
CD45.2 FITC  BD Pharmingen 
Troponin I  uncoupled Abcam 
4.3.8 Plaque assay 
Organ pieces frozen at -80°C were weighed and pestled in DMEM with 
Penicillin/Streptomycin. Three freeze-thaw cycles were followed by centrifugation at 
13000 rpm. A serial dilution of the supernatant was produced and 0.5 ml were added to Vero 
C1008 cells (seeded one day before at a density of 4x105 cells per well (6 well). Each sample 
was tested in 3 dilutions: 10-1 to 10-3. Another 0.5 ml media were added and the cells were 
incubated for 1h. The supernatant was removed and 5 ml Plaque assay medium were added. 
After incubation for 48h, cells were fixed with 1 ml 5% trichloracetic acid for 2h at room 
temperature, the overlay was removed and cells were stained with crystal violet to detect the 
plaques as light spots in the stained cell layer. 
medium for medium and supplements source of supply 
2x DMEM 26.76g DMEM  
7.4g NaHCO3 
ad 1l H2O dest., pH 7.2-7.4 
Gibco 
plaque assay medium 1:1 mixture of 
2x DMEM, 10% fetal calf serum and  
2% seaplaque agarose  
30 mM MgCl2 in H2O dest. 
 
 
Biozym 
crystal violet solution 0.25% crystal violet 
1.85% formalin 
10% ethanol 
35mM Tris Base 
0.5% CaCl2 
Merck 
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4.4 Molecular biology 
4.4.1 RNA isolation 
Organs were pestled in 1 ml Trizol (Invitrogen). 200 µl chloroform were added, and the 
solutions were mixed by thorough shaking and incubated at room temperature for 3 min. 
After centrifugation for 20 min at 4°C, 13000 rpm, the upper liquid phase containing the RNA 
was transferred into a new tube and 500 µl isopropanol were added. The RNA was 
precipitated at room temperature for 20 min, centrifuged for 20 min at 4°C, 13000 rpm and 
the supernatant was removed. The RNA was washed with 1 ml ethanol, centrifuged for 10 
min at 4°C, 13000 rpm, and diluted in 50-100 µl DEPC-H2O with 0.1 mM EDTA (Ambion) 
(depending on the pellet size). RNA isolation from cultured cells was performed with half the 
volume of solutions, centrifugation time was increased to 30 min, the RNA was precipitated 
at least 4h at 4°C or overnight at -20°C and diluted in 10-30 µl DEPC-H2O with 0.1 mM 
EDTA. RNA concentration was measured using a NanoDrop 1000 (PeqLab).  
4.4.2 cDNA synthesis 
500 ng RNA were diluted in 9 µl H2O (Aqua ad iniectabilia, Braun). Contaminating DNA 
was digested with 0.5 µl DNAse I (Ambion) for 15 min at 37°C, followed by enzyme 
deactivation for 5 min at 75°C. 2 µl random hexameres (0.5 µg/µl; TIB Molbiol) were added 
and the mixture was annealed 10 min at 70°C. Reverse transcription was performed at 37°C 
for 60 min with the following master mix: 4 µl 5x PCR buffer (Invitrogen), 2 µl DTT (0.1M, 
Invitrogen), 1 µl dNTPs (10mM each, Roche), 0.5 µl RNase Inhibitor (Roche), 1 µl MMLV 
Reverse Transcriptase (Invitrogen). All incubation steps were performed in a PCR cycler 
(Eppendorf Thermocycler Gradient).  
4.4.3 Quantitative real-time PCR/TaqMan® 
cDNA was diluted 1:1 in aqua ad iniectabilia (Braun) to a final concentration of 12.5 ng/µl. 
Reaction mix was prepared as indicated below. TaqMan® PCR was performed using the 
Applied Biosystems 7300 cycler and analyzed using SDS v1.3.1 software (Applied 
Biosystems). mRNA expression was normalized to the housekeeping gene HPRT by means of 
the ΔCt method. 
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Reaction mix using Gene Expression Assays (Applied Biosytems), FAM-none (non-fluorescent) 
final concentration or volume reagent source of supply 
0.5 µl 5 µM TaqMan® primers and 
probes 
Applied Biosystems 
6.5 µl TaqMan Universal PCR Gene 
Expression Master Mix  
Applied Biosystems 
1 µl cDNA (12.5 ng/µl)  
ad 13 µl aqua ad iniectabilia Braun 
Reaction mix using mHPRT, CVB3, IFN-γ, FAM-TAMRA 
final concentration or volume reagent source of supply 
0.5 µl probe (5 µM) Applied Biosystems 
6.5 µl TaqMan Universal PCR Gene 
Expression Master Mix  
Applied Biosystems 
1 µl cDNA (12.5 ng/µl)  
3 µl forward and reverse primers 
300 nM 
 
ad 13 µl aqua ad iniectabilia Braun 
TaqMan® PCR conditions 
temperature duration cycles 
50°C 2 min  
95°C 10 min  
95°C, 60°C 15 sec, 1 min 40x 
Primer and probe sequences mHPRT, CVB3, IFN-γ 
mHPRT forward: 5´-ATCATTATGCCGAGGATTTGGAA-3´ 
reverse: 5´-TTGAGCACACAGAGGGCCA-3  
probe: 5’FAM-TGGACAGGACTGAAAGACTTGCTCGAGATG-TAMRA-3’ 
CVB3 forward: 5’-TCCTCCGGCCCCTGA-3’ 
reverse: 5’-GATTGTCACCATAAGCAGCCA-3’ 
probe: 5’-FAM-CGGAACCGACTACTTTGGGTGTCCGT-TAMRA-3’ 
IFN-γ forward: 5’-AGCAACAGCAAGGCGAAAAA-3’ 
reverse: 5’-AGCTCATTGAATGCTTGGCG-3’ 
probe: 5’-FAM-ATTGCCAAGTTTGAGGTCAAACAACCCACA-TAMRA-3’ 
 28 
MATERIALS AND METHODS 
4.4.4 Microarray  
For microarray analysis, RNA (2 μg per time point/group, n=4) was sent to Signature 
Diagnostics AG (Postdam, Germany) for labelling, fragmentation and hybridisation to 
Affymetrix gene chips. The cDNA synthesis and in vitro transcription was performed using 
the Ambion MessageAmp™ Premier RNA Amplification Kit. Biotinylated cRNA was 
hybridized on Affymetrix U133 2.0 plus arrays. The hybridised chips were washed and 
stained on FS 450 fluidic stations and subsequently scanned on a GeneChip® Scanner 3000 
according to Affymetrix standard protocols. 
The scanner operating software converted the signal on the chip into a DAT file, which was 
used for generating subsequent CEL and CHP files for analysis. A quality check (QC) 
preliminary analysis was undertaken whereby the samples were required to conform to 
several parameters and quality checks before further analysis was performed. Further analysis 
was based on expression filter 20-100%, fold change≥2, GO analysis p-value <0.05; pairs of 
conditons. 
4.5 Protein biochemistry 
4.5.1 Isolation of 20S proteasomes and quantification of immunosubunits 
Five hearts were pooled and homogenized with Ultra Turrax in 5 ml homogenization buffer. 
After 10 to 20 min on ice, homogenates were centrifuged for 30 min at 17,000 rpm (JA25.5 
rotor). Supernatant was decanted and ammonium sulfate was added to 35% saturation. After 
20 min centrifugation at 14,000 rpm; 4°C, supernatant was concentrated by ammonium 
sulfate addition to 70% saturation. After 20 min centrifugation at 14,000 rpm; 4°C, pellets 
were dissolved in up to 2 ml TEAD buffer. Protein fractions were separated by ultra 
centrifugation on sucrose gradients (10 to 40%) and ultracentrifuged at 40,000 rpm for 16 hrs 
in a Beckman Coulter SW40 rotor. Fractions containing proteasomes were pooled and applied 
to a MonoQ® HR5/5 column (FPLC Amersham) and eluted with a linear gradient of 100 mM 
to 400 mM NaCl in TEAD. The proteolytic active fractions were collected. Immunoblot 
analysis of IP subunits was performed by separating 500 ng of purified proteasomes by SDS-
PAGE. Silver staining was performed to confirm equal load.  
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homogenization buffer  
10 mM Tris, pH 7.2  
0.1 mM EDTA  
10 mM NaCl  
25 mM KCl  
1.1 mM MgCl2  
10% glycerol  
1x complete  
10x TEAD  
20 mM Tris, pH 7.2  
1 mM EDTA  
1 mM azide  
add 1 mM DTT to 1x TEAD  
 
The relative quantification of proteasome subunits was carried out by Dr. Frank Schmidt/ 
Prof. Uwe Völker (Greifswald) (123).  
4.5.2 Silver staining 
Silver staining of proteins was performed according to a protocol by Heukeshoven and 
Dernick (modified) (124).  
procedure buffer  
fixing solution ≥ 1h 20 ml ethanol 
5 ml acetic acid  
ad 50 ml dist. H20 
 
sensitizing solution 30 min 15 ml ethanol 
250 µl glutaraldehyd (25%) 
2 ml sodium thiosulfate (5%) 
3.4g sodium acetate (MW 82.03g) 
 
wash 3x 5 min dist. H20   
silver staining solution 20 min 125 mg silver nitrate 
20 µl formalin (37% formaldehyde) 
ad 50 ml dist. H20 
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wash 2x 1 min dist. H20 dist. H20  
developing solution approx. 
20 min 
1.25g sodium carbonate 
10 µl formalin (37% formaldehyde) 
 
stop solution 10 min 750 mg sodium EDTA 
ad 50 ml dist. H20 
 
wash 3x 5 min dist. H20  
dry   
 
4.5.3 20S Proteasome activity 
100 ng purified 20S proteasomes were diluted in 11 µl of 1x TEAD buffer (see 4.5.1) and 
pipetted into a black 96 well microtiter plate. 50, 100, or 150 µM of fluorogenic substrates (Z-
LLE-AMC, Bz-VGR-AMC, and Suc-LLVY-AMC) were added in 100 µl 1x TEAD buffer. 
Free AMC was measured fluorometrically at ex.: 355 nm em.: 460 nm cut off: 455 nm for S-
LLVY and at ex.: 370 nm em.: 445 nm cut off: 435 nm for Z-LLE and Bz-VGR. 
4.5.4 Protein isolation and quantification 
For protein isolation, organs were pestled in 200 µl lysis buffer followed by 3 freeze-thaw 
cycles in liquid nitrogen and at 37°C, respectively. After centrifugation for 30 min at 4°C, 
13000 rpm, the supernatant was stored at -80°C. Adherent cells were washed with PBS, 
covered with 40 µl lysis buffer (12 well) and hold on ice for 10 min. Cells were then scraped 
off and centrifuged for 10 min at 4°C, 13000 rpm. For protein quantification, 5 µl protein 
solution was diluted with 20 µl distilled H2O. Lysis buffer diluted 1:5 in H2O was used as 
blank and a dilution series (1, 0.5, 0.25, 0.125, 0.025 µg/µl bovine serum albumin) was used 
as standard. 10 µl of each were pipetted in duplicates into a flat-bottom 96 well plate. 200 µl 
of BCA Protein Assay Reagent (Thermo Scientific) A:B = 50:1 were added and the plate was 
incubated for 30 min at 37°C and 10 min at room temperature before measuring the optical 
density at 570 nm in a plate reader (Anthos ht III). 
Lysis buffer (general)  inhibitors 
TrisHCl pH 7.5  10 µM MG132 
10 mM EDTA  5 mM NEM 
100 mM NaCl  1x complete 
1% NP40   
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Lysis buffer (for Oxy/Ub-staining)  inhibitors 
50 mM Tris HCl pH8 
150 mM NaCl 
1% NP40 
 for Oxy-Blot: only 1x complete 
for Ub-Blot: 1x complete, 10 µM MG132,  
                     5 mM NEM 
0.5% sodium deoxycholate (fresh)   
0.1% SDS 
1 mM EDTA 
  
4.5.5 SDS-PAGE and Western Blotting 
The protein lysate was diluted in distilled H2O to a volume of 20 µl and 6x loading buffer 
were added. Samples were denatured for 5 min at 95°C and then quickly cooled on ice. 
Samples and a molecular weight marker (Prestained Protein Ladder, Fermentas) were loaded 
on a polyacrylamid gel. The proteins were separated according to size by SDS-PAGE for 
approximately 1.5h at 150V, 50 mA, 100W (maximum). 
substance stacking gel 10% PAA    
separating gel 
15% PAA 
separating gel 
 
1M Tris pH 8.8 - 3.75 ml 3.75 ml  
1M Tris pH 6.8 3.75 ml - -  
acrylamide  
Rotiphoresegel 30 
1.95 ml 5 ml 7.5 ml  
distilled H20 9.15 ml 6.25 ml 3.75 ml  
TEMED 15 µl 10 µl 10 µl  
APS 75 µl 50 µl 50 µl  
loading buffer 6x Laemmli  SDS running buffer 1x 
6 ml glycerol  30.25g Tris 
7 ml 1M Tris pH 6.8  142.5g glycine 
2g SDS  10g SDS 
1.86g DTT  ad 1l distilled H20 
0.001g bromphenole blue 
ad 20 ml distilled H20 
  
 
Proteins were then transferred to a PVDF membrane (Immobilon-P, Milllipore) using a 
discontinuous semi-dry blotting method. The blotting chamber was assembled in the 
following order from anode to cathode: 4 layers of chromatographic paper (Whatman) in 
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anode buffer I, 3 layers of paper in anode buffer II, the membrane (activated in methanol and 
in anode buffer II), the gel (in anode buffer I) and 4 layers of paper in cathode buffer. The 
blotting occurred at 35 V, 400 mA, 5 W (maximum) for 1h 5 min and success of the transfer 
was controlled by reversible Ponceau S staining (0.5% solution). Membranes were incubated 
in Ponceau S for 3 min and destained by washing in distilled H2O. 
anode buffer I anode buffer II cathode buffer  
0.3 M Tris 25 mmol/l Tris -  
10% (v/v) methanol 10% (v/v) methanol 20% (v/v) methanol  
- - 40 mM 6-aminohexanoic acid  
- - 0.01% SDS  
distilled H20 ad 1l dist. H20 ad 1l dist. H20 ad 1l  
4.5.6 Immunoblot - protein detection 
To block unspecific binding of antibodies, membranes were incubated in PBS containing 10% 
RotiBlock (10x) for 1h at room temperature. Next, membranes were incubated with the 
primary antibody at 4°C over night while gently shaking. After washing 4 times for 5 min in 
washing buffer, the membranes were incubated with the secondary antibody for 1h at room 
temperature, followed by further 3 washing steps. The antibodies were diluted in PBS 
containing 10% RotiBlock. Proteins were detected by a chemoluminescent reaction with ECL 
Plus (GE Healthcare) according to manufacturer’s protocol. The membranes were posed on an 
x-ray film (CL-X Posure Film, Thermo Scientific), and the films were developed 
automatically (Colenta RDM8-1/S1, developing solution: X-OMAT EXII, fixing solution: RP 
X-OMAT LO, both Kodak). To remove bound primary antibodies, membranes were 
incubated in stripping buffer in a rotator for 30 min at 50°C. After washing twice in washing 
buffer for 10 min, blocking and protein detection were carried out as described above. 
stripping buffer washing buffer 
10 mM                   
2-mercaptoethanol 
PBS 
0.05% Tween 20 
2% (v/v) SDS  
62.5 mM Tris pH 6.7  
dist. H20 (boiled) ad 25 ml  
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Antibodies: 
target protein (clone) species clonality source of supply dilution 
GAPDH (FL-335) rabbit polyclonal Santa Cruz 1:1000 
β5i/LMP7 (K63) rabbit polyclonal lab stock 1:20000 
α6 (K379) rabbit polyclonal lab stock 1:20000 
β2i/MECL-1 (K65) rabbit polyclonal lab stock 1:5000 
target protein (clone) species clonality source of supply dilution 
β1i/LMP2 (ab3328) rabbit polyclonal Abcam  1:1000 
β1i/LMP2 (K620/21) rabbit polyclonal lab stock, cross-
reaction with β1  
1:1000 
GBP1 (M18) goat polyclonal Santa Cruz 1:1000 
ubiquitin (Z0458) rabbit polyclonal DAKO  1:1000 
CAR (H300) rabbit polyclonal Santa Cruz 200 µg/ml 
     
secondary antibody species conjugat source of supply dilution 
anti-rabbit IgG goat HRP Santa Cruz 1:5000 
anti-mouse IgG goat HRP Santa Cruz 1:5000 
anti-goat IgG donkey HRP Santa Cruz 1:5000 
4.5.7 Immunoblot- detection of oxidative stress 
Oxidized proteins were visualized with the OxyBlot protein oxidation detection kit 
(Chemicon International) via immunodetection of carbonyl groups. Carbonyl groups are 
derivatized to 2,4-dinitrophenylhydrazone (DNP) by reaction with 2,4-dinitrophenylhydrazine 
(DNPH). This derivatization captures the oxidative state immediately during or after 
homogenization of the tissue. DNP-derivatized protein samples are separated by 
polyacrylamide gel electrophoresis followed by Western blotting. Specific DNP antibody and 
HRP-coupled secondary antibody are used to visualize carbonyl-groups. OxyBlots were 
carried out by Daniela Ludwig/Prof. Elke Krüger (Berlin). 
4.5.8 Detection of CVB3- specific antibodies by ELISA 
Several dilutions of the serum in dilution buffer (Enterovirus ELISA Testkit, Genzyme 
Diagnostics) and dilution buffer used as blank were pipetted in duplicates into an antigen 
coated 96 well plate (Enterovirus ELISA Testkit, Genzyme Diagnostics). After incubation for 
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30 min at 37°C, the samples were removed and the plate was washed 4 times with washing 
buffer (PBS, 0.05% Tween20, pH 7.2-7.4). 100 µl of the secondary antibody (POX anti-
mouse IgG, Dianova) were added and incubated for 30 min at 37°C. After another washing 
step, 100 µl of a 1:1 mixture of the substrate solutions (TMB Substrate Reagent Set BD 
OptEIA, BD) A and B were added and incubated for 20 min at room temperature. The 
reaction was stopped with 50 µl 2M H2SO4, the plate was shaken and measured at 450 nm in 
a plate reader (Anthos ht III). CVB3-specific antibody titers are presented at the highest 
dilution of serum showing an optical density greater than the mean optical density of sera 
obtained from naive mice plus threefold the SD. 
4.5.9 NFκB ELISA 
After induction of IPs with 100 U/ml IFN-γ, primary cardiomyocytes and B-cell depleted 
splenocytes were stimulated with 30 ng/ml TNF-α for 30 min. p50 NFκB was determined in 
whole cell homogenates by ELISA according to the manufacturer's instructions 
(ActiveMotif). 
4.5.10 Luminex assay 
Serum samples from control and CVB3-treated mice were analyzed using the MILLIPLEXTM 
mouse cytokine/chemokine kit (Millipore) system according to the manufacturer’s 
instructions (n=5/group). Samples were measured using Luminex 200 xPONENT System 
[LX200 IS v.1.7, serial number LX10008099406] and xPONENT software 3.0.380.0.  
4.6 Statistical analysis 
Results of continuous variables are expressed as mean+standard error of mean (SEM) if not 
indicated otherwise. Data were analyzed using GraphPad Prism v5 software and IBM SPSS 
Statistics 19. Two group comparisons of non-parametric data were performed using the 
Mann-Whitney test. Statistical significance between multiple groups was determined using 
two-way ANOVA and post hoc analysis with a Bonferroni test. Significance was assessed at 
the p<0.05 level (* indicates significant differences).   
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4.7 Programs and websites 
programs websites 
SDS v1.3.1 NCBI www.pubmed.gov 
GraphPad Prism v5 ExPASy www.expasy.org 
Summit v4.3 EMBL-EBU www.ebi.ac.uk 
Image J v1.41o UniProt www.uniprot.org 
UNICORNTM  
IBM SPSS Statistics 19  
4.8 Appliances 
 source of supply 
agarose gel imager 
agarose electrophoresis chamber  
Intas 
Easy Cast B2 
gel blotting chamber PeqLab 
centrifuges Millifuge Millipore 
Heraeus Instruments Megafuge 1.0 
Heraeus Thermo Electron Corporation Fresco 17 
cryostat microtome Leica 
confocal microscope Leica TCS SP2 
developing machine Colenta RDM8-1/S1 
electrophoresis chamber (PAA gels) Hoefer 
electric pipettes Eppendorf 
fluorospectrometer PeqLab NanoDrop 1000 
fluorescence microscop Zeiss Axiovert 200M 
flow cytometer Beckman Coulter Cyan ADP  
BD FACSCalibur 
FPLC Amersham 
heating block Eppendorf Thermocycler Comfort 
hybridization oven HB-500, Minidizer, UVP 
incubator for cell culture, CO2 gased Biosafe Integra Bioscience 
 36 
MATERIALS AND METHODS 
 source of supply 
light microscop Leica Leitz DM IL 
magnetic stirrer Heidolph 
MACS magnet/rack Miltenyi Biotec 
micro scale Sartorius 
pH-meter WTW 
power supply Biometra Standard Power Pack P25 
PeqLab EV202 
PCR cycler Eppendorf Thermocycler Gradient 
plate reader Antosh ht III 
real time PCR cycler Applied Biosystems 7300 
sterile work banch LaminAir® HS9 Hereais Instruments 
shaker platform Rocky® LTF LAbortechnik 
shaker Heidolph Promax 1020 
ultra centrifuge Beckman Coulter SW40 
vortex mixer Heidolph Reax 2000 
vaccum pump KNF Lab 
water bath Memmert 
4.9 Consumables 
 source of supply 
BCA 96 well plate Greiner 
black 96 well plate Greiner 
centrifuge tubes 15,50 ml BD Falcon 
cryogenic tubes Sarstedt 
chromatographic paper Whatman® 
cell culture flasks 
cell culture plates 6,12,24 well 
BD Falcon  
BD Falcon 
cell strainer 40,70 µm BD Falcon 
canula 26G 1/4 BD Falcon 
CL-X Posure Film Thermo Scientific 
disposable pipettes 1,2,5,10,25 ml BD Falcon 
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 source of supply 
ELISA 96 well plate Nunc 
FPLC GE Healthcare, Amersham 
FACS tubes Micronic, Falcon 
MACS columns Miltenyi Biotec 
Neubauer chamber, hemocytometer Digital Bio 
PVDF membrane Immobilon-P, Millipore 
pipette tips 10,20,100,200,1000 µl Sarstedt 
parafilm American National Can 
reaction vessels 0.5,1,2 ml Sarstedt 
RTQ opical 96 well reaction plate Applied Biosystems 
sterile filter Whatman® 
sterile syringes 2,5,10 ml BD Falcon 
sterile syringe 1 ml BD Falcon 
super frost object slides R Langenbrinck 
4.10 Chemicals 
 source of supply 
2-mercaptoethanol Western blot: Sigma Aldrich 
cell culture: GIBCO 
6-aminohexanoic acid Merck 
Ammonium sulfate Serva 
APS Serva 
Acrylamide (Rotiphoresegel 30) Carl Roth GmbH&Co 
Azetic acid Merck 
Ammonium chloride Fluka 
Aqua iniectabilia Braun 
BSA AppliChem 
BCA protein assay reagent Thermo Scientific 
Bromphenol blue Biomol 
Calcium chloride Sigma 
Chloroform Merck 
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 source of supply 
Complete protease inhibitor Roche 
Crystal violett Merck 
DEPC-H20 (0.1 mM EDTA) Ambion 
DAPI AppliChem 
DTT Sigma Aldrich 
ECL Plus Amersham 
Ethanol J.T. Baker  
EDTA TitriplexIII Merck 
FCS Biochrom AG 
Formaldehyde Merck 
Glycerol Merck 
Glutaraldehyde Serva 
Glycine Roth 
H2O2 Merck 
Isopropanol J.T. Baker 
Isofluran (Forene®) Abbott 
IFN-γ Roche 
Immumount Thermo Scientific 
Methanol Carl Roth GmbH&Co 
Magnesium chloride Fluka 
MG132 Calbiochem 
NEM Fluka 
PBS PAA Laboratories 
Ponceau S Sigma 
Penicillin/Streptomycin (10000 U/ml) Biochrom AG  
Potassium hydrogen carbonate Merck 
Potassium chloride Merck 
Roti®-Block 10x Carl Roth GmbH&Co 
Roti® Histofix (4%PFA) Roth 
SDS Roth 
Seaplaque agarose Biozym 
Sodium hydrogen carbonate Sigma 
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 source of supply 
Sodium carbonate Sigma 
Sodium azide Fluka 
Sodium citrate Sigma 
Sodium chloride Carl Roth GmbH&Co 
Sodium thiosulfate Merck 
Sodium acetate Roth 
Silver nitrate Roth 
Sodium EDTA Serva 
Tris Base Carl Roth GmbH&Co 
Tissue-Tek Sakura 
TNF-α Roche 
Trizol Ambion 
Trypan blue ICN BIochemicals 
Tween® 20 Serva 
TEMED Sigma Aldrich 
Triton® X-100 Ferak 
Xylene J.T.Baker 
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5.1 Phenotypic characterization of β1i/LMP2-/- and β5i/LMP7-/- 
mice 
To obtain insights concerning the function of IPs in CVB3-associated myocarditis, detailed 
characterization of IP-competent C57BL/6 as well as β5i/LMP7-/- and β1i/LMP2-/- mice was 
performed at an early (d4 p.i.), acute (d8 p.i.), and chronic (d28) stage of disease.  
5.1.1 Determination of myocardial damage by hematoxylin-eosine staining  
First, myocardial infection was histologically correlated to the extent of lymphocyte 
infiltration and myocyte necrosis by hematoxylin-eosine staining. Apart from a few scattered 
macrophages, no focal inflammatory infiltrates were detectable in the hearts of C57BL/6, 
β5i/LMP7-/- and β1i/LMP2-/- mice at d4 p.i. (Fig. 5A). At the same time point, the pancreas as 
the primary organ of CVB3 replication was massively inflamed in all three strains. At d8 p.i, 
pancreatic acinar cell destruction with fibrous and fatty tissue replacement was observed in 
β5i/LMP7-/- mice. By comparison, some pancreatic cells were still present in C57BL/6 and 
particularly in β1i/LMP2-/- mice at this time point. This referred to accelerated pancreas 
destruction in β5i/LMP7-deficient mice early upon CVB3 infection (Fig. 5B).  
Moreover, massive myocyte necrosis was detected in β5i/LMP7-/- mice at d8 p.i. as 
representatively illustrated in Fig. 5A. Inflammatory lesions were considerably larger than in 
C57BL/6 mice. By contrast, myocardial damage was found to be less pronounced in 
β1i/LMP2-/- mice as compared to C57BL/6. Quantification of heart muscle injury resulted in a 
significantly higher myocarditis score of 2.8±0.2 in β5i/LMP7-/- mice vs. 2.0±0.14 in 
C57BL/6 mice (*p<0.05). Small inflammatory foci and marginal myocyte necrosis revealed a 
significantly lower myocarditis score in β1i/LMP2-/- mice (0.6±0.08; *p<0.01) as compared to 
C57BL/6 mice. In C57BL/6 and β1i/LMP2-/- mice, no relevant signs of ongoing chronic 
myocardial inflammation were observed at d28 p.i. (Fig. 5A). Also, only marginal 
inflammatory lesions were observed in β5i/LMP7-/- mice at this time point.  
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Fig. 5 Quantification of myocardial inflammation. Hematoxylin-eosine (HE-) stainings of heart (A) and 
pancreas (B) sections of different time points post infectionem are shown (representative for n≥10 mice/group). 
C: Myocardial damage was quantified by applying a myocarditis score from 0 to 4 (0: no inflammatory 
infiltrates, 1: small foci of inflammatory cells between myocytes, 2: larger foci of >100 inflammatory cells, 3: 
≤10 % of cross-section involved, 4: 10 to 30 % of a cross-section involved) (*p<0.001, one-way ANOVA; n≥9 
mice+SEM). 
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To further characterize the composition of inflammatory lesions, immunohistological 
stainings of C57B/6 and β5i/LMP7-/- heart sections were evaluated. The major fraction of 
invading inflammatory cells was comprised of Mac-3+ macrophages and CD3+ T lymphocytes 
in both strains (Fig. 6A). Quantification of positive cell signals per visual field at a 20-fold 
magnification resulted in significantly enhanced absolute numbers of T lymphocytes in 
β5i/LMP7-/- mice as compared to C57BL/6 mice (Fig. 6B). 
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Fig. 6 Characterization of myocardial lesions. A: Immunostaining for CD3+ T lymphocytes and Mac-3+ 
macrophages was performed. Representative d8 p.i. cardiac tissue sections are shown (n≥6 mice/group). No 
specific signals were detected in non-infected control mice. B: Quantification of immunohistochemically 
positive cells in C57BL/6 and β5i/LMP7-/- heart sections was achieved by counting all positive cells per visual 
field at a magnification of x20 (n≥5 mice/group+SEM). C: The mRNA expression of T cell-induced cytotoxic 
mediators was determined by quantitative real-time PCR in the hearts of C57BL/6 and β5i/LMP7-/- mice at d0, 
d4, and d8 p.i. (n≥6 mice+SEM). 
Significantly more Mac-3+ macrophages were found in β5i/LMP7-/- mice, whereby the 
differentiation of single signals was limited due to massive infiltration and staining, thus 
quantitative data do not reflect absolute macrophage numbers here. In non-infected control 
mice, no specific CD3+ T cell or Mac-3+ cell signals were detected.  
Despite significant differences in T cell numbers, mRNA levels of perforin, granzyme A and 
granzyme B, which are released by cytotoxic T cells to eliminate virus-infected cells (125), 
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were detected to be within the same range in CVB3-infected C57BL/6 and β5i/LMP7-
deficient hearts as determined by quantitative real-time PCR (Fig. 6C). 
5.1.2 Investigation of cardiac function by microconductance pressure 
catheter measurement 
Myocarditis-associated inflammation and cardiac cell necrosis can cause acute heart failure. 
With respect to the myocarditis scores of β5i/LMP7-/- and β1i/LMP2-/- mice, it was important 
to assess the left ventricular (LV) function at the acute stage of disease. Heart rate (HR), 
systolic and diastolic LV function were determined by microconductance pressure-volume 
catheter measurements in sham-treated and CVB3-infected mice at d8 p.i.  
As shown in Table 1, HR was constant over the course of infection in all three strains. Also, 
no baseline differences for parameters of the systolic or diastolic performance were 
detected in non-infected β5i/LMP7-/- and β1i/LMP2-/- mice as compared to C57BL/6 mice. 
Upon CVB3 infection, acute heart muscle injury in C57BL/6 and β5i/LMP7-/- mice was 
accompanied by an impaired systolic function at d8 p.i. as compared to their respective sham-
treated controls (C57BL/6/β5i/LMP7-/-: dP/dtmax -22.9/-28.9 %, LV Pmax -18.2#/-21.1# %, SV -
23.5/-23.1 %). The EF, defined as the fraction of blood that is ejected out of the left ventricle 
relative to its end-diastolic volume, is reduced in β5i/LMP7-/- (-12 %), but not in C57BL/6 
and β1i/LMP2-/- mice.  
 
Table 1 Investigation of left ventricular function by microconductance catheter measurement. Systolic and 
diastolic LV function was determined in sham-treated and CVB3-infected animals at d8 p.i. (n≥5 female 
mice/group±SEM, Two-Way ANOVA (SPSS): #statistical significance indicates strain-specific differences 
between d8 p.i. vs. respective controls d0 p.i., p<0.05). 
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Furthermore, diastolic LV function limitations were monitored in CVB3-infected C57BL/6 
and β5i/LMP7-/- mice as demonstrated for the minimum rate of pressure change dP/dtmin. This 
parameter of left ventricular relaxation was reduced in both, C57BL/6 and β5i/LMP7-/- mice at 
d8 p.i. (C57BL/6/β5i/LMP7-/-: dP/dtmin -22.2/-21.4 %). In agreement with the limited 
myocardial damage in β1i/LMP2-/- mice (Fig. 5A), cardiac function was preserved in these 
mice. Systolic and diastolic LV function parameters of CVB3-infected β1i/LMP2-/- mice were 
found to be in the same range as sham-treated C57BL/6 control mice.  
5.1.3 Determination of viral load by in situ hybridization, qRT-PCR and 
plaque assay 
The question whether the divergent phenotype of β5i/LMP7-/- respectively β1i/LMP2-/- mice 
was attributed to different CVB3 replication was analyzed by the determination of the viral 
load. As demonstrated by CVB3 in situ hybridization (ISH), virus positive cardiomyocytes 
were detected within inflammatory lesions (Fig. 7A), a fact that is pathognomonic in viral 
myocarditis. Scoring of CVB3-positive cardiomyocytes suggested equal viral replication in 
both, C57BL/6 and β5i/LMP7-/- mice, whereas the ISH score of β1i/LMP2-/- mice was 
significantly lower (Fig. 7B). Furthermore, titers of infectious CVB3 particles were found to 
be within the same range in heart homogenates of C57BL/6 and β5i/LMP7-/- mice as 
determined by plaque assay (Fig. 7C). In agreement with the lower ISH score, the viral load 
was found to be considerably reduced in heart homogenates of β1i/LMP2-/- mice (Fig. 7C). 
Observations from in situ hybridization and plaque assay were confirmed by quantitative real-
time PCR, which demonstrated equal CVB3 replication in C57BL/6 and β5i/LMP7-/- hearts at 
an early and acute stage of disease. By contrast, viral replication was significantly reduced in 
β1i/LMP2-/- hearts. At a late stage of myocarditis, CVB3 replication was below the detection 
level in all three mice strains (Fig. 7D). 
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Fig. 7 Investigation of viral load. A: Representative strand-specific in situ hybridizations for genomic CVB3 
RNA (black dots) in d8 p.i. hearts of C57BL/6, β5i/LMP7-/- and β1i/LMP2-/- mice are illustrated. B: The amount 
of CVB3 RNA detected by in situ hybridization of cardiac tissue sections was scored within a range from 0 to 4 
(n≥5 mice/group). C: The amount of infectious viral particles in d8 p.i. hearts of CVB3-challenged mice was 
determined by plaque assay. D: Viral replication in CVB3-infected hearts was analyzed by real-time PCR at 
indicated time points (n≥7+SEM, *p<0.05). 
To exclude potential in vivo factors that might have contributed to the restricted viral load in 
β1i/LMP2-/- mice, viral replication was examined in isolated primary cardiomyocytes. The 
purity of these in vitro cultures was determined by FACS analysis of troponin I expression, 
which is a heart muscle-specific protein. On average, more than 93 % of isolated cells 
expressed troponin I as exemplarily shown in Fig. 8B. Primary cardiomyocytes were infected 
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at MOI 0.5 and viral replication was determined by quantitative real-time PCR. No 
differences in CVB3 replication were detected in β5i/LMP7-deficient cells compared to 
C57BL/6 wildtype cells (Fig. 8 left panel). On the contrary, viral replication was found to be 
restricted in β1i/LMP2-/- cardiomyocytes (Fig. 8 right panel), which confirmed the in vivo 
findings. The use of different virus stocks and TaqMan master mixes for experiments with 
β5i/LMP7-/- and β1i/LMP2-/- cardiomyocytes may account for divergent relative expression 
values. 
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Fig. 8 Viral replication in primary cardiomyocytes. A: Purity of primary cardiomyocytes was determined by 
flow cytometry using a cardiomyocyte-specific troponin I antibody. Representative histograms are shown. B: 
CVB3 replication in primary C57BL/6 and β5i/LMP7-/- respectively C57BL/6 and β1i/LMP2-/- (C) 
cardiomyocytes was analyzed by quantitative real-time PCR. Cells were prestimulated with IFN for 24 h to 
induce IP-formation and infected at MOI 0.5 for 8 h. Data are representative for 3 independent experiments 
(*p<0.01).  
5.1.4 Characterization of cardiac IP formation by qRT-PCR, Western blot 
analysis and mass spectrometry 
To explain the function of IPs in the context of CVB3 myocarditis, information about the 
subunit composition of β5i/LMP7-/- and β1i/LMP2-/- proteasomes was required. Therefore, 
cardiac mRNA was isolated and 20S proteasomes were purified from sham-treated and 
CVB3-infected heart homogenates. 
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Fig. 9 Characterization of 20S proteasomes of CVB3 challengend mice. A: Cardiac mRNA expression of 
β1i/LMP2, β2i/MECL1, and β5i/LMP7 was quantified by real-time PCR in sham-treated control mice and at d4 
and d8 p.i. (n≥5 mice/group+SEM). B: Subunit incorporation was investigated by immunoblotting of purified 
cardiac 20S proteasomes (α6 and silverstaining as loading controls). Data are representative for two individual 
20S proteasome purifications (pool of n=5 mice per group and experiment). 
As determined by quantitative real-time PCR, mRNA expression of β1i/LMP2 was induced in 
C57BL/6 and β5i/LMP7-deficient hearts upon CVB3 infection. Expression of β5i/LMP7 
mRNA was enhanced in C57BL/6 and β1i/LMP2-deficient hearts; and MECL-1 mRNA 
expression was increased in all three strains at d4 p.i. (Fig. 9A). Immunoblot analysis of 
purified 20S proteasomes demonstrated similar levels of β5i/LMP7 and β2i/MECL-1 subunits 
in C57BL/6 and β1i/LMP2-deficient hearts at d4 and d8 p.i. By contrast, 20S proteasomes 
isolated from CVB3 infected β5i/LMP7-/- hearts showed no β2i/MECL-1 and only impaired 
β1i/LMP2 incorporation (Fig. 9B). 
Quantification of each proteasome subunit within the 20S core was performed by high 
resolution LTQ-Orbitrap mass spectrometry (MS) analysis after separation of cardiac tryptic 
peptides by reverse phase nano HPLC. In C57BL/6 hearts, all three inducible subunits 
β1i/LMP2 (3.5-fold induction; p<0.05), β2i/MECL-1 (2.6-fold induction; p<0.05), and 
β5i/LMP7 (2.0-fold induction; p=0.10) were enhanced at d4 p.i. By contrast, neither 
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β1i/LMP2 (1.3-fold; p=0.67) nor β2i/MECL-1 (1.5-fold; p=0.38) were found to be increased 
in cardiac 20S proteasomes of β5i/LMP7-/- mice at this stage of disease.  
A 
C57BL/6 / 
β5i/LMP7-/- 
control  d4 p.i.  d8 p.i.  
  Ratio   p-value  Ratio       p-value  Ratio          p-value  
α2  1.18 0.51 1.01 0.99 1.03 0.93 
β4  1.17 0.51 1.06 0.84 1.12 0.68 
β1  1.19 0.48 1.18 0.63 1.1 0.72 
β2  1.37 0.29 1.27 0.5 1.08 0.77 
β5  1.12 0.71 0.96 0.91 0.76 0.41 
β5i/LMP7  n.d. - n.d. - n.d. - 
β1i/LMP2  1.32 0.48 3.7 0.04 1.82 0.18 
β2i/MECL1  5.25 0.01 9.18 < 0.001 2.64 < 0.001 
B 
C57BL/6 / 
β1i/LMP2-/-  
control  d4 p.i.  d8 p.i.  
  Ratio  p-value  Ratio  p-value  Ratio  p-value  
α2  1.26 0.46 1.05 0.87 0.94 0.86 
β4  1.21 0.46 1 0.99 0.94 0.8 
β1  1.26 0.41 1.15 0.65 1.08 0.79 
β2  1.54 0.19 0.97 0.91 0.95 0.88 
β5  1.39 0.38 1.11 0.76 0.96 0.92 
β5i/LMP7  1.14 0.64 0.97 0.93 1.12 0.65 
β1i/LMP2  n.d. - n.d. - n.d. - 
β2i/MECL1  3.59 0.025 4.38 0.0031 3.83 < 0.001 
Table 2 Quantification of cardiac 20S proteasome subunits by mass spectroscopy. 20S proteasomes were 
isolated from heart homogenates of sham-treated or CVB3-infected mice. The total 20S fraction was separated 
into subtypes by reverse phase nano HPLC prior to mass spectroscopy (Orbitrap-MS). MS ion intensities are 
shown for each proteasome subunit as a ratio between C57BL/6 and β5i/LMP7-/- mice (A) respectively C57BL/6 
and β1i/LMP2-/- mice (B). Data represent mean±SD from two technical replicates, each perfomed with two 
biological replicates (*p<0.05, n.d.: ratio not determined in β5i/LMP7-/- respectively in β1i/LMP2-/- mice, 
statistical significance is based on C57BL/6 wildtype controls). 
In accordance with mRNA expression data and immunoblot analysis of β1i/LMP2-deficient 
heart homogenates, β5i/LMP7 (2.9-fold; p=0.001) and β2i/MECL-1 (2.8-fold, p=0.003) 
subunits were incorporated into β1i/LMP2-/- 20S complexes at d4 p.i. despite the lack of 
β1i/LMP2. As expected, no significant differences in the presence of constitutive catalytic and 
non-catalytic subunits were detected (as exemplarily shown for β1, β2, β5 respectively α2 and 
β4). Notably, β5i/LMP7-/- (5.25-fold, p=0.01) and β1i/LMP2-/- (3.59, p=0.025) mice show 
baseline deficits to incorporate β2i/MECL-1 as compared to C57BL/6 mice (Table 2A/B). 
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This failure was exacerbated over the course of CVB3 infection. Incorporation of β5i/LMP7 
was not affected by β1i/LMP2-deficiency, neither in naive nor in CVB3-challenged hearts 
(Table 2B). These data point towards a substantial impairment of IP assembly in β5i/LMP7-/- 
mice and the expression of intermediate proteasomes in β1i/LMP2-/- mice during acute 
myocarditis. 
5.2 Characterization of the adaptive immune response in 
β1i/LMP2-/- and β5i/LMP7-/- mice 
During the effector phase of a virus-specific adaptive immune response, CD8+ T cells migrate 
to the target organ of infection. The cytotoxic T cell (CTL) response to pathogens is directed 
against antigenic epitopes, that are processed by proteasomes and presented by MHC class I 
molecules. Immunoproteasomes have been shown to optimize the quantity and quality of 
peptide ligands in several infection models. Due to the finding that a potent CD8+ T cell 
response is important to mediate CVB3 virus elimination (33;126), it was of great interest to 
investigate the effect of β1i/LMP2- and β5i/LMP7-deficiency on CD8+ T cell immunity in 
CVB3 myocarditis. Previous in vitro processing studies demonstrated, that cardiac IP 
formation is linked to the preferential generation of CVB3-specific epitopes as compared to 
standard proteasomes (118).  
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Fig. 10 Frequencies of CVB3 epitope-specific T cells in acute myocarditis. CD8+ T cells isolated from naive 
and CVB3-infected C57BL/6 mice (d8 p.i.) were stained with H-2Db VP2 [285-293]-PE and H-2Kb P3D [2170-
2177]-PE pentamers vs. CD8-FITC. A: Representative dot plots for each pentamer are shown. Cells in the upper 
right quadrant indicate CVB3-specific CD8+ T cells. B: The average percentage of pentamer-positive CD8+ T 
cells is illustrated (n=4+SEM *p< 0.05). 
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To test the potential of these epitopes to elicit an antigen specific CD8+ T cell response in 
vivo, CD8+ T cell were isolated from sham-treated and CVB3-infected C57BL/6 mice and 
stained with epitope-specific P3D [2170-2177] and VP2 [285-293] phycoerythrin (PE)-
coupled pentamers.  
FACS analysis revealed a CVB3-specific response in infected C57BL/6 mice, that was 
predominantly directed against P3D [2170-2177] and to a lesser extend against VP2 [285-
293] (Fig. 10B). 
5.2.1 CD8+ T cell function 
Overall P3D- and VP2-specific CD8+ T cell frequencies were rather low (<1 %, see Fig. 10) 
and the existence of other, so far unknown epitopes could not be excluded. To study whether 
IP-deficiency has an impact on the function of CD8+ T cells despite these limitations, 
adoptive transfer of cytotoxic CD8+ T cells was performed. For this purpose, CD8+ T cells 
were isolated from total splenocytes of CVB3-infected C57BL/6 wildtype, β1i/LMP2-/- and 
β5i/LMP7-/- donor mice, respectively. MACS separation resulted in at least 89 % purity of 
CD8+ T cells as representatively shown in Fig. 11.  
 
Fig. 11 Purity of CD8+ T cells. CD8+ T cells were isolated from total splenocytes of CVB3-infected animals by 
MACS separation. After fluorescent labeling of cells with anti-CD3-FITC and anti-CD8-PB antibodies, purity 
was determined by flow cytometry. Representative dot blots indicate the percentage of CD3+/CD8+ T cells prior 
and after MACS separation. 
To preclude effects of IP-deficiency on T cell survival, CD8+ T cells from CVB3-challenged 
β5i/LMP7-/- and β1i/LMP2-/- mice (both CD45.2) were transferred into B6.SJL-Ptprca 
Pepcb/BoyJ mice (CD45.1) and vice versa. After transfer, recipient mice were immediately 
infected, and the amount of donor CD8+ T cells was determined at d8 p.i. Therefore, total 
splenocytes were stained with anti-CD8-PB and anti-CD45.1-PerCPCy5 respectively anti-
CD45.2-FITC antibodies and analyzed by flow cytometry.  
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Fig. 12 Adoptive CD8+ T cell transfer. 1–2×106 CD8+ T cells were transferred from one CVB3 infected 
C57BL/6 (CD45.1) into one β5i/LMP7-/- respectively β1i/LMP2-/- (CD45.2) mouse and vice versa. Recipient 
mice were infected with CVB3 and the survival of donor CD45.1 and CD45.2 T cells was determined by FACS 
analysis at d8 p.i. A: The gating strategy is exemplarily shown for the transfer of CD8+ T cells from C57BL/6 
(CD45.1) respectively β5i/LMP7-/- (CD45.2) mice and vice versa. B/C: The average percentage of donor CD8+ 
T cells is illustrated (n=5 mice/group). D/E: After transfer of donor CD8+ T cells and CVB3 infection, the 
myocardial damage of the recipient mice was evaluated by hematoxylin-eosine staining at d8 p.i. (n=5 
mice/group, representative for two independent experiments, *p<0.05). 
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CD8 positive T cells were gated as illustrated in Fig. 12A and the fraction of donor 
CD8+/CD45+ T cells was determined.  
Deficiency of β5i/LMP7 had no effect on T cell survival in the respective recipients (Fig. 
12B). By contrast, donor CD8+ T cells from β1i/LMP2-deficient mice showed decreased 
survival rates as compared to IP-competent lymphocytes (Fig. 12C).  
To get more functional insights concerning CD8+ T cell responses with respect to the target 
organ of CVB3 infection, heart tissue injury was assessed after adoptive transfer of CD8+ T 
cells by hematoxylin-eosine staining. Myocarditis scores of β5i/LMP7-competent and 
β5i/LMP7-deficient recipient mice were found to be within the same range, independent from 
the origin of donor CD8+ T cells (Fig. 12D). By contrast, myocarditis scores of β1i/LMP2-/- 
recipient mice were significantly lower compared to C57BL/6 recipients (Fig. 12E). 
However, no protective or deleterious effects on the extent of acute myocardial injury were 
observed in these recipients upon transfer of β1i/LMP2-competent or β1i/LMP2-deficient 
CD8+ T cells. 
5.2.2 Determination of CVB3-specific IgG titers by ELISA 
B cells isolated from C57BL/6 mice preferentially express IPs (127), and a CVB3-specific 
IgG antibody response contributes to an efficient virus elimination in CVB3 myocarditis 
(128). Therefore, it was important to characterize the function of IPs for the induction of a 
systemic B cell response in CVB3 myocarditis. CVB3-specific antibodies IgG titers were 
determined in sera of C57BL/6, β5i/LMP7-/- and β1i/LMP2-/- mice at d8 and d28 p.i. 
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Fig. 13 Determination of CVB3-specific antibody titers. Titers of virus-specific IgG antibodies were assessed 
in sera of C57BL/6, β5i/LMP7-/- and β1i/LMP2-/- mice at indicated time points by a CVB3-specific ELISA 
(n≥8+SEM). 
Serum levels of anti-CVB3 IgG antibodies were within the same range in all three 
investigated strains at d8 p.i. (Fig. 13). By day 28 p.i., an increase of IgG titers was observed, 
 53 
RESULTS 
whereby no strain-specific differences were detected, which demonstrated that β5i/LMP7- and 
β1i/LMP2-deficient mice were capable of generating an efficient high affinity antibody 
response. 
5.2.3 Characterization of splenic cell subpopulations by FACS analysis  
As mentioned before, immune cells, including T and B cells as well as professional APCs 
such as dendritic cells, constitutively express IPs (129;130). To investigate whether IP 
expression is important for the maintenance of homeostatic T and B cell levels, the percentage 
of splenic CD3+/CD4+, CD3+/CD8+ T cells, and CD19+/B220+ B cells was determined by 
FACS analysis over the course of CVB3 infection. The relative amount of CD4+ T, CD8+ T 
and B cells was not affected in sham-treated or CVB3-infected β5i/LMP7-/- mice as compared 
to C57BL/6 mice.  
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Fig. 14 FACS analysis of total splenocytes. Single splenocyte suspensions of C57BL/6, β5i/LMP7-/- and 
β1i/LMP2-/- mice were prepared and the percentage of splenic subpopulations was determined by flow cytometry 
at d0, d4 and d8 p.i. A: CD3+/CD4+, CD3+/CD8+ T cells, and CD19+/B220+ B cells were gated as demonstrated 
and B: the the relative amount of these subpopulations was determined (n≥8 mice/group,*p<0.05). 
By contrast, the relative amount of CD8+ T cells was significantly reduced in sham-treated 
β1i/LMP2-/- mice and in CVB3-infected β1i/LMP2-/- mice at d4 p.i., whereas no differences in 
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the relative number of CD4+ T cells as well as B cells were observed as compared to C57BL/6 
wildtype mice (Fig. 14B). 
Interestingly, quantification of total splenocytes resulted in significantly lower absolute 
numbers in naive β1i/LMP2-/- control mice as compared with C57BL/6 and β5i/LMP7-/- 
control mice (Fig. 15A). Upon CVB3 infection, a 3-fold increase in total splenocytes was 
observed in β1i/LMP2-/- mice in contrast to C57BL/6 and β5i/LMP7-/- mice at d8 p.i. 
Absolute numbers of splenic subpopulations were determined in naive mice by multiplying 
splenic frequencies by the total cell number (per spleen). As illustrated in Fig. 15B, naive 
β1i/LMP2-/- mice had significantly reduced baseline numbers of splenic CD4+, CD8+ and B 
cells. Splenic hyperplasia as observed upon CVB3 infection in β1i/LMP2-/- mice explains 
equal relative amounts of CD8+ T cells in β1i/LMP2-/- mice compared to C57BL/6 mice at 
d8 p.i. (Fig. 7 middle panel). 
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Fig. 15 Quantification of absolute splenocyte numbers in naive mice. A: The absolute number of splenocytes 
was determined by counting total splenocytes. B: Subsequent calculation of CD3+/CD4+, CD3+/CD8+ T cell and 
CD19+/B220+ B cell numbers based on ratios from FACS analysis by multiplying splenic frequencies by the 
total number of cells from each spleen (n≥4, *p<0.05). 
5.3 The function of β1i/LMP2-/- in CVB3 myocarditis 
The protective phenotype of β1i/LMP2-/- mice in CVB3 myocarditis was not expected, as 
β1i/LMP2- deficiency was previously linked to detrimental effects on the antiviral immune 
response as shown for influenza A infection models (127;131). To exclude the possibility that 
differences in the expression of the coxsackie- and adenovirus receptor (CAR) caused 
diminished viral replication in β1i/LMP2-/- mice, immunoblot analysis of heart homogenates 
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was performed. CAR expression was shown to be within the same range in β1i/LMP2-/- and 
IP-competent C57BL/6 mice (Fig. 16).  
 
 
Fig. 16 Investigation of CAR expression. CAR expression was determined in heart homogenates of C57BL/6 
and β1i/LMP2-/- mice by Western blot analysis. GAPDH is shown as loading control (pool of n=5 mice). 
5.3.1 Gene expression analysis by Affymetrix microarray  
A whole genome gene expression profile was generated in order to identify possible pathways 
or signaling regulators that may contribute to restricted viral replication in β1i/LMP2-/- mice. 
Affymetrix GeneChip microarray analysis revealed the transcriptional regulation of various 
genes that were differently expressed in CVB3-challenged β1i/LMP2-/- hearts as shown for 
intensity profiles in Fig. 17A (n=4). In sham-treated β1i/LMP2-/- mice, mRNA expression of 
interferon inducible genes Ifi202b, histocompatibility antigen HA-28 and guanylate binding 
protein GBP-1 was detected. Notably, mRNA levels of these genes significantly increased 
during the early phase of CVB3 infection, whereas no expression was detected in C57BL/6 
mice, neither in sham-treated control mice nor upon CVB3 infection. These data pointed 
towards a more general effect of β1i/LMP2-deficiency on the modulation of interferon-
induced pathways. 
Several cytokine effector pathways mediate the antiviral response by the degradation of viral 
RNA, blocking of viral transcription, or inhibition of translation. Four major pathways are 
involved: the ISG15 ubiquitin-like pathway (IFN-stimulated gene 15), the Mx-GTPase 
pathway (Myxovirus resistance protein), the protein kinase K pathway (PKR), and the 2′-
5′oligoadenylate-synthetase-directed ribonuclease L pathway (OASL-2) (132). Interestingly, 
ISG15, Mx1, and PKR were differentially regulated in β1i/LMP2-/- mice over the course of 
CVB3 infection. To verify these findings, mRNA expression was confirmed by quantitative 
real-time PCR (n=6, p<0.05, Fig. 17B). 
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Fig. 17 Affymetrix microarray expression profiles and mRNA expression of potentially antiviral 
molecules. A: The affymetrix microarray heatmap depicts the regulation of genes over the course of CVB3 
infection (fold change β1i/LMP2-/- to C57BL/6; color as illustrated, n=4 mice/group). B: Cardiac expression of 
indicated molecules at d4 and d8 p.i. was determined in the hearts of C57BL/6 and β1i/LMP2-/- mice by 
quantitative real-time PCR (n=6+SEM, *p<0.05). 
5.3.2 Determination of the host genetic background by SNP analysis  
At this stage, the completely different mRNA expression pattern in CVB3-
infected β1i/LMP2 -/- vs. IP-competent C57BL/6 hearts raised serious doubts, whether 
β1i/LMP2-deficient mice were of the required genetic background (C57BL/6). To address this 
question, a PCR-based single nucleotide polymorphism (SNP) panel was applied. The 
examined markers are spread across the genome at about 7 Mbp intervals, and allow the 
differentiation between the commonly used inbred mice strains C57BL/6(J), C57BL/6(N), 
SvJ/129, and C57BL/6 (JOlaHsd).  
As illustrated in Fig. 18, a knockout animal is normally backcrossed against the required 
genetic background (here C57BL/6(J)), and with each filial generation, the average 
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percentage of the constant background increases. After sufficient reiterations, an animal of the 
desired knockout is of the required genetic background (N10, >99.9 % C57BL/6). 
Unfortunately, the analyzed samples only ranged from 82.68 % to 83.72 % C57BL/6(J) 
background, indicating that the animals had not been backcrossed to C57BL/6 for 10 
generations.  Instead, they looked like SvJ/129-C57BL/6 F1 offsprings that had been 
intercrossed for 10 generations (F10 instead of N10). SvJ/129 mice are frequently used to 
isolate embryonic stem cells, which can be modified by homologous recombination by gene 
targeting vectors (133). Importantly, these mice show a mild inflammatory response and 
diminished viral replication after CVB3 infection (134-136). Thus, the beneficial outcome of 
the β1i/LMP2-/- mice in comparison to C57BL/6 mice was rather caused by the genetic 
background than by the deletion of β1i/LMP2. Due to this finding, all obtained data regarding 
myocardial inflammation and viral replication cannot be interpreted appropriately. 
Hereinafter, the mixed background of β1i/LMP2-/- mice will be indicated as β1i/LMP2-/- 
(C57BL/6xSvJ129). 
 
 
 
Fig. 18 Backcrossing scheme. 10 β1i/LMP2-/- mice were tested for their genetic background by a SNP panel 
directed against C57BL/6(J), C57BL/6(N) and SvJ/129 markers. Instead of correct backcrossing with C57BL/6 
mice in order to obtain a constant genetic background of >99.9 % (right hand side), β1i/LMP2-/- offsprings of the 
F1 generation had been intercrossed (left hand side).  
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5.3.3 Characterization of myocardial damage and virus replication in 
C57BL/6xSvJ129 mice 
To prove the idea that background artifacts caused the protective phenotype in β1i/LMP2-
deficient mice and to re-examine the function of β1i/LMP2 in CVB3 myocarditis, myocardial 
damage was determined in β1i/LMP2-competent and β1i/LMP2-deficient mice, both having a 
mixed C57BL/6xSvJ129 background. For this purpose, β1i/LMP2-/- (C57BL/6xSvJ129) mice were 
crossed with C57BL/6(J) mice and CVB3 infection experiments were performed in 
β1i/LMP2+/+ (C57BL/6xSvJ129) and β1i/LMP2-/- (C57BL/6xSvJ129) offsprings of the third filial 
generation (F3) (see Fig. 19A). Myocardial damage of CVB3-infected β1i/LMP2-competent 
and β1i/LMP2-deficient C57BL/6xSvJ129 mice was analyzed by hematoxylin-eosine staining 
at d8 p.i.  
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Fig. 19 Myocardial inflammation and CVB3 replication in C57BL/6xSvJ129 mice. A: β1i/LMP2-/- 
(C57BL/6xSvJ129) mice were crossed with C57BL/6(J) animals as depicted and CVB3 infection experiments were 
repeated in offsprings of the F2 generation. B: The myocarditis score was determined in cognate β1i/LMP2+/+ 
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(C57BL/6xSvJ129) and β1i/LMP2-/- (C57BL/6xSvJ129) mice at d8 p.i. (F2 generation; n=10 mice/group) by HE-staining. C: 
Primary cardiomyocytes were isolated from cognate β1i/LMP2+/+ (C57BL/6xSvJ129) and β1i/LMP2-/- (C57BL/6/SvJ129) 
mice, infected at MOI 0.5 and harvested 8 h p.i. CVB3 replication was investigated by quantitative real-time 
PCR. Data are representative for 3 individual experiments. 
By contrast to previous experiments in C57BL/6(J) and β1i/LMP2-/- (C57BL/6xSvJ129) mice, heart 
tissue injury was found to be within the same range in both, β1i/LMP2+/+ (C57BL/6xSvJ129) and 
β1i/LMP2-/- (C57BL/6xSvJ129) mice (1.2±0.2 vs. 1.1±0.3; *p<0.05, Fig. 19B).  
This finding indicates that β1i/LMP2-deficiency has no effect on the outcome of murine 
CVB3 myocarditis. Nevertheless, one has to keep in mind that the genetic background close 
to the target gene always reflects the original embryonal stem cell strain (133;137). Therefore, 
it is possible that the true effect of β1i/LMP2-deficiency in C57BL/6xSvJ129 mice was 
concealed by artifical transcriptional regulation.  
Albeit detrimental impacts of β1i/LMP2-deficiency cannot be conclusively excluded in vivo, 
in vitro infection experiments of β1i/LMP2+/+(C57BL/6xSvJ129) and β1i/LMP2-/-(C57BL/6xSvJ129) 
cardiomyocytes strongly supported the notion that β1i/LMP2-deficiency has no influence on 
murine CVB3 myocarditis. Primary cardiomyocytes from β1i/LMP2+/+ (C57BL/6/SvJ129) and 
β1i/LMP2-/- (C57BL/6/SvJ129) mice (see Fig. 19A) were pre-stimulated with IFN-γ to induce the 
expression of immunosubunits, infected at a MOI 0.5 and harvested after 8 h. CVB3 
replication was then investigated by quantitative real-time PCR. By striking contrast to 
significantly reduced CVB3 replication in β1i/LMP2-/- (C57BL/6/SvJ129) cardiomyocytes in 
comparison to C57BL/6 wildtype cells (see Fig. 8A, right panel), no differences in viral 
replication were observed here (Fig. 19C). It is worth mentioning, that primary cells were 
isolated from up to 25 embryos per experiment. For that reason, genetic variability owing to 
the mixed C57BL/6xSvJ129 background was statistically better compensated in vitro than in 
vivo, where only ten animals per group were analyzed.  
As the analysis of mixed background animals is experimentally unfavored, no further 
experiments concerning proteasome constitution or regulation of IFN-γ pathways were 
performed in β1i/LMP2-competent and -deficient C57BL/6xSvJ129 mice. 
5.4 The function of β5i/LMP7-/- in CVB3 myocarditis 
The background of the β5i/LMP7-deficient mice contained approximately 98.4 % C57BL/6-
specific gene loci, which corresponds to the sixth backcross generation (N6). Consequently, 
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exacerbated CVB3-associated myocardial inflammation in β5i/LMP7-deficient mice was not 
caused by genetic background artifacts, but rather by the lack of intact IP-formation. The fact 
that both, C57BL/6 and β5i/LMP7-/- mice showed identical viral load, similar levels of CTL 
effectors, and viral clearance by d28 p.i. argued in favor of an effective CD8+ T cell response 
in β5i/LMP7-/- mice. These findings point towards other functions of β5i/LMP7 in the present 
model. 
5.4.1 Determination of cytokine expression by qRT-PCR and Luminex® 
assay 
Cytokines such as TNF-α, IFN-γ, and IL-6 are expressed in the myocardium upon CVB3 
infection, which triggers immune cell infiltration (2;27). To study whether the in vivo 
cytokine response potentiated the inflammatory damage in β5i/LMP7-/- mice, TNF-α, IFN-γ, 
IFN-β, and IL-6 mRNA expression levels of CVB3-challenged hearts were determined by 
quantitative real-time PCR. The cardiac expression of the pro-inflammatory cytokines was 
induced in both, C57BL/6 and β5i/LMP7-/- mice upon CVB3 infection, but no strain-specific 
differences were observed for TNF-α, IFN-β, and IL-6 (Fig. 20). Only the mRNA level of 
IFN-γ was significantly increased in β5i/LMP7-/- hearts at d8 p.i.  
Among others, IFN-γ induces the expression of IP-10 (IFN-γ-induced protein 10), which is an 
chemoattractive signal for macrophages and T cells. Also RANTES (regulated upon 
activation, normal T-cell expressed, and secreted), which is induced by TNF-α, recruits 
leucocytes to inflammatory lesions. To study whether differences in the expression of these 
regulatory proteins caused exacerbated inflammation, circulating levels of selected cytokines 
were measured in serum samples using a fluorescent bead-based assay system (Luminex®). 
However, serum levels of TNF-α, RANTES, IP-10, and MCP-1 (monocyte chemotactic 
protein-1) were found to be within the same range in both hosts during early inflammation 
(Fig. 21). 
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Fig. 20 mRNA expression of inflammatory cytokines. Expression of the indicated cytokines was assessed by 
quantitative real-time PCR in the hearts of C57BL/6 and β5i/LMP7-/- mice at d4 and d8 p.i. (n≥5 mice+SEM, 
*p<0.05). 
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Fig. 21 Serum levels of cytokines. Serum levels of selected cytokines were analyzed by multiplex Luminex® 
assay at d4 and d8 p.i. (n≥5 mice+SEM). 
5.4.2 Investigation of antiviral defense mediators by qRT-PCR 
The expression of cytokines and antiviral genes is regulated early upon infection by a highly 
complex signaling system. For example, PKR mediates the activation of the central regulator 
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NF-κB, which in turn induces the expression of interferons. To analyze whether a differential 
expression of the antiviral pathway mediators ISG15, Mx1, PKR and OASL-2 played a role in 
the aggravation of inflammation in β5i/LMP7-/- mice, cardiac mRNA expression of these 
genes was determined in C57BL/6 and β5i/LMP7-deficient mice by quantitative real-time 
PCR. Upon CVB3 infection, mRNA expression levels increased in both, C57BL/6 and 
β5i/LMP7-/- mice (Fig. 22), but no strain-specific differences were detected. 
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Fig. 22 mRNA expression of innate antiviral molecules. The cardiac expression of indicated antiviral 
molecules at d4 and d8 p.i. was determined in the hearts of C57BL/6 and β5i/LMP7-/- mice by quantitative real-
time PCR (n≥5 mice+SEM). 
5.4.3 Quantification of poly-Ub conjugates and oxidative protein damage 
by immunoblot analysis and immunofluorescence 
As described above, exacerbated myocardial damage was detected in β5i/LMP7-deficient 
mice despite the induction of an effective antiviral response. Also, expression of pro-
inflammatory cytokines was not enhanced in β5i/LMP7-/- mice, neither in the target organ of 
CVB3 infection nor systemically. Considering the importance of proteasomes for the 
maintenance of the cellular protein homeostasis, it was therefore necessary to study whether 
intact IP formation plays a critical role for proteostasis in response to cytokine-induced stress.  
As demonstrated, macrophages and T lymphocytes, that generally express IPs, represent the 
major fraction of the cellular infiltrate in CVB3-infected hearts (see Fig. 6), whereby B cells 
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are negligible. Upon virus infection, macrophages are activated and release pro-inflammatory 
cytokines such as TNF-α, but also reactive oxygen species (ROS) (138;139). Notably, 
exposure to cytokines (e.g. TNF-α) can induce ROS generation in non-infected target cells as 
well (140). This pro-inflammatory milieu represents a highly reactive environment for 
cardiomyocytes but also for the inflammatory cell itself. As a consequence of oxidative 
modification by oxygen free radicals or other reactive species, carbonyl groups are introduced 
into protein side chains in a site-specific manner. Here, it was investigated whether IPs are 
required to adapt to cytokine-induced protein accumulation and oxidation in cardiomyocytes 
and inflammatory cells.  
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Fig. 23 Poly-ubiquitylation and oxidation of proteins in inflammatory cells and primary cardiomyocytes. 
A: Purity of B cell depleted splenocytes was determined after MACS separation by flow-cytometry, using 
B220+/CD19+ specific antibodies. Representative histograms are shown. B: Immunoblots of poly-ubiquitylated 
proteins and proteins that are modified by carbonyl groups are shown for IFN-γ treated primary cardiomyocytes 
and B-cell depleted splenocytes from C57BL/6 and β5i/LMP7-/- mice. GAPDH illustrates equal protein loading. 
Images are representative for two independent experiments. 
Isolated primary cardiomyocytes and B cell depleted splenocytes from C57BL/6 and 
β5i/LMP7-/- mice were stimulated with 100 U/ml IFN-γ. Purity of B cell depleted splenocytes 
was controlled by flow cytometry yielding > 97 % as exemplarily shown in Fig. 23A. Cell 
lysates were either directly immunoblotted and stained for poly-Ub conjugates or carbonyl-
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groups were first derivatized with 2,4-dinitrophenylhydrazine. 2,4-dinitrophenylhydrazone 
(DNP)-derivatized protein samples were then immunoblotted and stained for DNP.  
Following IFN-γ stimulation, poly-ubiquitylated proteins accumulated in β5i/LMP7-deficient 
but not in C57BL/6-derived cardiomyocytes (Fig. 23B). Also, the accumulation of poly-Ub 
conjugates was stronger in IP-deficient than in IP-competent inflammatory cells. Detection of 
carbonyl groups by OxyBlotTM kit demonstrated, that the impairment of IP-formation in 
β5i/LMP7-/- cardiomyocytes and inflammatory cells was associated with increased 
accumulation of oxidatively modified proteins (Fig. 23B). 
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Fig. 24 NF-κB p50 expression levels. Whole cell homogenates from IFN-γ pre-treated primary cardiomyocytes 
and B cell-depleted splenocytes were prepared after 30 min TNF-α stimulation. NF-κB p50 expression levels 
were determined by ELISA (ActiveMotif). Data are shown as fold increase of p50 levels in TNF-α-treated cell 
lysates compared to untreated control samples (*p<0.05, representative means from triplicates from at least two 
independent experiments). 
To test whether the enhanced protein accumulation in cytokine-exposed IP-deficient cells 
affected cell signaling, the level of activated NF-κB was determined. NF-κB is a central 
regulator of diverse signaling pathways. The treatment of primary cardiomyocytes and 
inflammatory cells with 30 ng/ml TNF-α resulted in the impaired activation of NF-κB in IP-
deficient cells (Fig. 24). This finding reflected the reduced proteasomal degradation of NF-κB 
p105 precursor proteins, which was in line with the decreased capacity of IP-deficient cells to 
remove protein aggregates (Fig. 23). 
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Fig. 25 Poly-ubiquitylation and oxidation of proteins in heart homogenates. A: Immunoblot of heart 
homogenates from CVB3 infected C57BL/6 and β5i/LMP7-/- mice, stained for poly-Ub proteins and carbonyl 
groups (d8 p.i., n=5, representative for n=10 mice). B: Densitometry was performed for individual lanes 
(n=5+SEM, * p<0.05). 
The examination of CVB3-infected hearts confirmed that β5i/LMP7-deficiency also results in 
prolonged protein aggregation in vivo. As shown by immunoblot analysis of heart 
homogenates, poly-ubiquitylated, oxidant-damaged proteins accumulated in acutely inflamed 
β5i/LMP7-/- hearts at d8 p.i. (Fig. 25A). Densitometric quantification of individual lanes 
resulted in significantly increased poly-Ub and DNP signal intensity (Fig. 25B). 
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Fig. 26 Formation and localization of poly-ub proteins. A: Immunofluorescence staining of poly-Ub proteins 
was performed in heart cryosections of naive and infected C57BL/6 and β5i/LMP7-/- mice. White arrowheads 
mark poly-Ub ALIS (representative for n=6 mice and two independent experiments). B: ALIS were quantified in 
defined areas of cryosections of CVB3-challenged hearts (1088 μm2 at 200-fold magnification, n=5 
areas/section, n=6 mice/group, *p<0.05). C: Immunohistochemical staining for ubiquitin was applied in paraffin 
sections of of naive and infected C57BL/6 and β5i/LMP7-/- mice (n≥7, representative sections are shown). 
As a generalized stress response, the formation of aggresome-like structures (ALIS) is 
induced in several immune and non-immune cell types to store poly-ubiquitylated proteins 
transiently prior to the degradation by the proteasome (113). To study whether β5i/LMP7-
deficiency affects ALIS-formation in CVB3 myocarditis, heart tissue sections were stained 
for poly-Ub proteins. In both, C57BL/6 and β5i/LMP7-/- heart sections, cytosolic ALIS were 
detected upon CVB3 infection as compared to sham-treated controls (Fig. 26A). However, 
impairment of IP-formation in β5i/LMP7-/- cells was linked to significantly increased 
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aggresome-like induced structures. Quantification of ALIS revealed 14.6 
ALIS/1088 µm2 ± 1.2 in C57BL/6 mice vs. 22.4 ALIS/1088 µm2 ± 2.3 in β5i/LMP7-/- mice 
(n=5, *p<0.05). As demonstrated by immunohistolochemical staining, these poly-Ub 
conjugates were primarily detected in invading inflammatory cells and within the cytoplasm 
of adjacent cardiomyocytes (Fig. 26C). 
5.4.4 Determination of apoptotic cell death by immunofluorescence 
Cardiomyocyte apoptosis is a hallmark of CVB-associated myocardits (141). However, direct 
cytopathic effects of CVB3 replication cannot explain aggravated myocardial damage as 
observed in β5i/LMP7-/- mice, because CVB3 titers were found to be within the same range as 
compared to C57BL/6 mice. To address the question, whether increased aggregation of 
oxidized and poly-ubiquitylated proteins in β5i/LMP7-/- mice affected the viability of 
β5i/LMP7-/- cells, genomic DNA fragmentation as an early sign for apoptosis was determined 
in cardiac tissue sections by in situ cell death detection kit/TMR red. No signs of apoptosis 
were detected in C57BL/6 and β5i/LMP7-/- mice at d4 p.i. (Fig. 27A).  
At the acute stage of disease (d8 p.i.), TUNEL positive signals were found solely in the 
myocardium of β5i/LMP7-/- mice. As demonstrated by POD-coupled immunohistochemical 
analysis, these apoptotic foci exactly corresponded to invading cellular infiltrates and adjacent 
cardiomyocytes (Fig. 27B). By contrast, despite the presence of minor inflammatory lesions 
in CVB3 challenged C57BL/6 hearts, no significant signs of apoptosis were detectable at 
d8 p.i. here (Fig. 27A). 
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Fig. 27 Analysis of apoptotic cell death. A: Apoptosis was investigated in vivo by the application of the in situ 
cell death detection TMR red kit to cardiac tissue sections of naive and CVB3-challenged mice (d8 p.i.). 
Representative sections from two independent experiments (n=5 mice/experiment) are shown. B: Localization of 
apoptosis was assessed by using the in situ cell death detection POD kit.  
5.4.5 Gene expression analysis by Affymetrix microarray  
To get a comprehensive impression of signaling pathways that were potentially involved in 
excessive inflammation and apoptosis in β5i/LMP7-/- mice, a cardiac gene expression pattern 
was generated using RNA from sham-treated and CVB3-infected C57BL/6 and β5i/LMP7-/- 
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mice. As CVB3 infection is associated by the induction of reactive oxygen species (142),  the 
activation of the unfolded protein response, and the increase of apoptosis due to ER-stress 
(143), it was of interest to focus on these pathways. Affymetrix GeneChip microarray analysis 
revealed a threefold induction of the redox-sensitive nuclear factor Nrf2 exclusively in 
C57BL/6 hearts upon CVB3 infection, whereas no changes in the mRNA expression were 
detected in β5i/LMP7-/- hearts. Equal cardiac mRNA levels of enzymes which mediate the 
cellular oxidative stress response such as catalase (Cat), glutathione (Gpx), or superoxide 
dismutase (Sod) were observed. However, the mRNA expression of the Nrf-2-responsive 
genes Nqo1 (NAD(P)H dehydrogenase) and Gclc (glutamate-cysteine ligase catalytoc 
subunit) were solely increased in infected C57BL/6 hearts.  
 
 
Fig. 28 Affymetrix microarray expression profile. The affymetrix microarray heatmap illustrates the 
regulation of genes over the course of CVB3 infection (fold change color as illustrated, n=4 mice/group). 
Although pathophysiological stress conditions such as viruses are described to activate the 
heat shock response, expression of the major transcription regulator Hsf1 or heats shock 
proteins (Hsp70, Hspa5) was not induced.  
Also, no transcriptional induction of the UPR-related genes IRE/Xbp1, PERK, Atf4 or Atf6 
was found neither in C57BL/6 nor in β5i/LMP7-/- hearts at the acute stage of disease. By 
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contrast, a fourfold increase of the proapoptotic transcription factor CHOP (DNA damage-
inducible transcript 3 protein) was observed in both hosts at d4 and d8 p.i.  
Expression of the sterol regulatory element-binding protein 1 (SREBP1), which is also 
involved in the apoptotic pathway, was slightly up-regulated in β5i/LMP7-/- mice, but not in 
C57BL/6 mice at d8 p.i. Further analysis revealed a strong increase of cardiac pentaxin 3 
(Ptx3) mRNA expression in C57BL/6 mice at d8 p.i., which was abrogated concomitantly to 
impaired IP-formation in β5i/LMP7-/- hearts. Notably, baseline expression levels of all 
indicated genes were found to be in the same range in both hosts. The differential regulation 
of Nrf2, Ptx3, as well as SREBP2 in IP-deficient hearts upon CVB3 infection thus implicated 
an involvement of IPs in cell signaling pathways. 
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Over the last years, the complexity of the ubiquitin-proteasome system (UPS) and the 
particular role of immunoproteasomes have become apparent. As part of the adaptive immune 
response, IPs were initially reported to optimize MHC class I antigen processing. Far from 
being entirely investigated, the functional spectrum of IPs was extended to various cellular 
functions in which standard proteasomes are involved, such as the regulation of cell signaling 
and differentiation, apoptosis, and transcription (63). The present study contributes to the 
understanding of IP-function, demonstrating the importance of IP-formation for the 
preservation of proteostasis in inflammatory viral heart disease. 
6.1 The proteasome constitution in β1i/LMP2- and β5i/LMP7-
deficient hearts upon CVB3 infection 
In accordance with a study by Hensley et al. (117), an efficient incorporation of β2i/MECL-1 
and β5i/LMP7 was detected in β1i/LMP2-deficient hearts upon CVB3 infection (see Fig. 9B). 
This observation is contradictory to previous studies that demonstrated cooperative assembly 
mechanisms, whereby the presence of β1i/LMP2 was shown to facilitate the incorporation of 
β2i/MECL-1 (144;145). These differences can be explained by the fact that the present system 
based on IP- induction by IFN-γ and in vivo infection, whereas Griffin and Kingsbury et al., 
who described cooperative assembly mechanisms, investigated steady state cell lines with 
fixed expression of standard and immunosubunits (71;144). In contrast to the expression of 
intermediate proteasomes in β1i/LMP2-/- mice, β5i/LMP7-deficiency led to impaired 
incorporation of β2i/MECL-1 and β1i/LMP2 (see Fig. 9B). A conflicting study by Joeris et al. 
only recently showed that β5 subunits integrate into LMP2/MECL-1 precursor proteasomes in 
β5i/LMP7-deficient cells upon IFN-γ stimulation. Furthermore, they demonstrated that 
Listeria monocytogenes infection of β5i/LMP7-deficient mice results in the expression of 
mixed LMP2/MECL-1/β5 proteasomes in the liver (146). Joeris et al. suggest that the 
integration of standard or immunosubunits depends on competition on protein level rather 
than on cooperative assembly mechanisms (146). However, this cannot explain why the 
incorporation of β2i/MECL-1 and β1i/LMP2 was impaired in CVB3-infected β5i/LMP7-/- 
hearts despite the induction of their respective genes on transcriptional level (see Fig. 9A). 
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Instead, the present findings point towards complex proteasome assembly mechanisms in a 
tissue- and/or disease-dependent manner. 
6.2 IP-formation is not necessary for an effective CD8+ T cell response 
in CVB3 myocarditis 
Standard and immunoproteasomes display distinct proteolytic activities (96;147), resulting in 
the generation of a different CTL epitope repertoire (148). Along with the fact that Henke and 
Klingel et al. demonstrated the involvement of CD8+ CTLs in the limitation of initial CVB3 
replication (33;126), it was necessary to clarify the contribution of IPs to CVB3 epitope 
processing and to the induction of an effective CD8+ T cell response in vivo. However, the 
here studied CVB3-specific MHC class I epitopes only elicit weak CD8+ T cell responses 
(118;149). In contrast to classical viral mouse models like LCMV or Influenza virus infection, 
overall epitope-specific CD8+ T cell quantities were found to be rather low in CVB3-infection 
as shown here for CVB3 VP2 [285-293]-specific CD8+ T cells (see Fig. 10B). Therefore, 
adoptive CD8+ memory T cell transfer experiments were performed, which additionally 
included potential effects of so far not identified CVB3-specific CD8+ T cell epitopes. The 
average percentage of β1i/LMP2-deficient donor cells in their respective recipient mice was 
considerably low (see Fig. 12C). These data are in line with the study by Hensley et al., that 
demonstrated decreased lymphocyte survival in influenza A virus-challenged β1i/LMP2-
deficient mice (127). However, the restricted β1i/LMP2-/- lymphocyte survival had no 
demonstrable consequence. The myocarditis scores of the recipient C57BL/6 or β1i/LMP2-/- 
mice were found to be within the same range, independent from the origin of donor 
lymphocytes (see Fig. 12E). The observed difference of myocardial inflammation between 
C57BL/6 and β1i/LMP2-/- recipients was first attributed to a general impact of β1i/LMP2-
deficiency (compare Fig. 5A). However, the attenuation of acute CVB3 myocarditis in 
β1i/LMP2-deficient mice was found to be due to background artifacts later on. As 
demonstrated in detail (see section 5.3), the deletion of β1i/LMP2 had actually no effect on 
the outcome of viral heart disease. Therefore, the reduced lymphocyte survival as observed by 
CD8+ T cell transfer experiments cannot be properly discussed in the present context. 
By contrast, the survival of transferred CD8+ T cells from C57BL/6 or β5i/LMP7-/- donors 
was found to be within the same range (see Fig. 12B). No beneficial effects on CVB3 
myocarditis were detected after transfer of CD8+ T cells isolated from IP-competent as 
compared with transfer of CD8+ T cells from β5i/LMP7-/- mice (see Fig. 12D). However, 
transfer of IP-competent and IP-deficient CD8+ T cells resulted in a slightly milder 
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myocarditis than in non-transferred animals (compare Fig. 5A). In agreement with the fact 
that both, C57BL/6 and β5i/LMP7-/- mice demonstrated equal viral loads and perforin 
expression at the acute stage of disease (see Fig. 7B/C; Fig. 6C), and were both able to 
effectively eliminate virus and inflammation by d28 p.i. (see Fig. 7D), intact cardiac IP-
formation was not mandatory for the induction of a sufficient CD8+ T cell response in viral 
heart disease.  
These data are in line with findings by Nussbaum et al., which showed that β5i/LMP7-
deficiency has no considerable effect on overall CD8+ T cell responses to lymphocytic 
choriomeningitis virus infection and does not alter the kinetics of virus clearance (150). By 
contrast, Kincaid et al. showed that DCs of triply deficient (LMP2/MECL1/LMP7-/-) mice 
have substantial defects in presenting several MHC class I epitopes. Also, the CD8+ T cell 
response to LCMV-specific epitopes is lower and the immunodominance hierarchy is 
markedly altered in these mice (151). They attributed their findings to the fact, that a 
functional overlap of immunosubunits in mixed proteasomes masks the true importance of IPs 
for MHC class I presentation (151). These data must not necessarily be contradictory to the 
present study. First, the impaired incorporation of β1i/LMP2 and β2i/MECL1 in β5i/LMP7-
deficient hearts upon CVB3 infection was almost equivalent to a triple knockout as 
investigated by Kincaid et al. However, one cannot directly compare different infection 
models. LCMV elicits a vigorous CD8+ T cell response that persists at high levels (152), 
whereas CVB3 infection only results in a weak virus-specific primary CTL response (153). 
Second, Kincaid et al. solely investigated the impact of IP-formation on MHC class I epitope 
processing by professional antigen presenting cells (APCs), which constitutively express IPs. 
Therefore, a complete IP-knockout might have more severe functional consequences in APCs 
than in cardiomyocytes, whose primary function is not antigen presentation. The present study 
focused on the function of IPs in the heart, once the induction of a CD8+ T cell response was 
excluded from being a disease-modifying factor. 
6.3 Impaired IP formation in β5i/LMP7-deficient mice results in 
deteriorated acute CVB3 myocarditis  
The fact that T lymphocytes and non-infected cells within pathogen-challenged tissues 
express IPs without having a function as antigen-presenting cells (63;69;154) already 
indicates that IPs do not exclusively facilitate antigen processing. Indeed, the sufficient CD8+ 
T cell response in β5i/LMP7-/- mice argued in favor of MHC class I-independent functions of 
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IPs in the present model. The constitutive knockout of cardiac immunosubunits caused a 
massive exacerbation of myocardial inflammation upon CVB3 infection (see Fig. 5), 
accompanied by deteriorated systolic and diastolic left ventricular heart function at d8 p.i. (see 
Table 1). Importantly, the ejection fraction as one major determinant of cardiac function was 
reduced in β5i/LMP7-/- mice, but not in IP-competent C57BL/6 mice upon CVB3 infection. 
The lack of statistical power has to be discussed in view of the fact that the infection 
efficiency decisively depends on age and body weight of the mice. Due to these experimental 
requirements, the dropout rate in the hemodynamically analyzed group of CVB3-infected 
β5i/LMP7-/- mice was high. As an appropriate sample size is closely related to statistical 
power, more animals would have been required to detect potential strain-specific differences. 
Nevertheless, further experiments demonstrated that IP-formation in murine C57BL/6 hearts 
protected from the accumulation of polyubiquitylated and oxidatively damaged proteins, as 
well as from enhanced apoptosis of inflammatory cells and cardiomyocytes. 
6.3.1 IP-formation protects from aggravated accumulation of poly-Ub and 
oxidatively damaged proteins  
Many cell types that are affected by pathogens produce type I interferons as part of the innate 
inflammatory response (155). Activated T-lymphocytes, macrophages, and NK cells secrete 
various proinflammatory cytokines such as IFN-γ and TNF-α (156), which do not only induce 
the formation of IPs, but also increase protein synthesis via downstream activation of the 
mTOR pathway (157). As reported by Si et al., CVB3 infection generates reactive oxygen 
species (ROS) (142). Moreover, cytokine-exposed cells, whether they are infected or not, 
produce ROS and reactive nitrogen (RNS) species e.g. by NADPH-oxidases (NOX) (158). 
Free radicals do not selectively neutralize pathogenic proteins, but give rise to oxidative 
damage of cellular proteins, whereby newly synthesized proteins are particularly sensitive to 
proteotoxic stress (159). Taken together, it becomes evident that exposure to cytokines 
massively challenges the protein equilibrium. Concomitant with CVB3 infection, oxidative 
stress and virus-induced alterations of the cellular translation machinery (113;160) may cause 
the enhanced incurrence of DRIPs. If the degradation capacity of proteasomes is exceeded, 
DRiPs, long-lived or nascent, poly-ubiquitylated and/or oxidant damaged proteins are 
temporarily accumulated in aggresome-like induced structures (113). However, excessive 
protein accumulation upon cellular stress is inherently cytotoxic (117;161). To meet this 
challenge to proteostasis, the UPS as the key regulator of protein quality control and 
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physiological protein turnover adapts to pro-inflammatory conditions. UBE2L6 as the major 
E2-conjugating enzyme as well as the Lys-48 linked polyubiquitylation of proteins is 
upregulated (162), and IPs are expressed by the de novo synthesis (38;162). Thereby, the 
poly-Ub substrate degradation capacity is enhanced (162). As evidenced by Jakel et al., 
cardiac IP formation is directly linked to increased peptide-hydolyzing activity in CVB3 
myocarditis (118). The present study correlates the induction of cardiac IPs to the enhanced 
degradation of oxidant-damaged, poly-Ub proteins in viral heart disease. 
Here, IFN-γ stimulated IP-deficient primary cardiomyocytes and inflammatory cells were 
shown to accumulate poly-Ub, oxidant-damaged proteins. Remarkably, IP-competent cells 
were able to adapt to cytokine-triggered cellular stress, as they prevented prolonged 
aggregation of potentially toxic proteins in vitro (see Fig. 23). These findings are in line with 
a study by Seifert et al., which recently reported an association between IP-formation and the 
ability to clear ALIS in murine embryonal fibroblasts (MEFs). This is attributed to the 
augmented capactity of IPs to degrade K48-linked poly-Ub substrates (162). The transient 
increase of polyubiquitylated proteins and the coincident decrease of proteasomal activity 
after IFN-γ stimulation of non-lymphoid cells can be explained by the dissociation of the 
standard 26S proteasome until IPs are synthesized after approximately 24 hours. On the basis 
of their capacity to turn over polyubiquitylated substrates two-fold or three-fold faster than 
standard proteasomes, IPs represent an adaptation of cells to cope with tremendous 
physiological stress conditions arising e.g. from infection or cytokine exposure (162). 
Furthermore, the present study demonstrates that the induction of cardiac IPs is crucial for the 
efficient degradation of poly-Ub, oxidant-damaged proteins in vivo (see Fig. 25). IP-deficient 
mice failed to efficiently degrade ALIS in the injured myocardium (see Fig. 26). These poly-
Ub and potentially oxidized proteins were detected within inflammatoy foci and within the 
cytoplasm and nuclei of adjacent cardiomyocytes (see Fig. 26). These results are in agreement 
with data by Seifert et al., that highlight the importance of IPs in experimental autoimmune 
encephalomyelitis (EAE), the most intensively studied animal model for multiple sclerosis 
(163). In EAE, IP-formation is accompanied by less severe disease manifestation (162). 
Beyond that, failures in the elimination of aggregates are associated with the pathogenesis of a 
wide range of human diseases including cystic fibrosis, Alzheimer's disease, or Parkinson’s 
disease (164). 
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6.3.2 IP-deficient hearts are prone to apoptotic cell death 
The 26S proteasome can play opposite roles in the regulation of apoptotic cell death, because 
both, negative and positive mediators undergo proteasomal degradation in a tightly regulated 
and timely controlled manner (165). A study by Yang et al. strongly supports the assumption 
that IPs contribute to apoptosis regulation. They detected accelerated degradation of the 
potent pro-survival factor MCL-1 (induced myeloid leukemia cell differentiation protein 1) 
upon IFN-γ-induced IP-formation, thereby reducing cellular viability (166). On the contrary, 
Seifert et al. demonstrated that β5i/LMP7-deficient fibroblasts are highly susceptible to 
apoptosis in response to IFN-γ and the apoptosis-inducer etoposide, as reflected by enhanced 
caspase 3/7 activity (162). Related to viral heart disease, the present work demonstrates that 
IP-formation prevented apoptotic cell injury of CVB3-challenged inflammatory cells and 
adjacent cardiomyocytes (see Fig. 27). As CVB3 infection was recently reported to activate 
the unfolded protein response and to trigger ER stress-mediated apoptosis (143), one may 
argue that deficits in protein degradation as found in IP-deficient β5i/LMP7-/- mice 
additionally challenge cellular stress-responsive mechanisms. Here, mRNA expression of the 
central player of the cytosolic heat shock stress response, Hsf1, was not altered upon CVB3 
infection, neither in C57BL/6 nor in β5i/LMP7-deficient hearts. Also, no differences in the 
cardiac mRNA expression of ERAD- or protein folding-associated chaperones such as 
SEL1L, p97/VCP or Hsp70 were detected (see Fig. 28). These findings lead to the 
conclusion, that increased protein accumulation in β5i/LMP7-/- cells was not attributed to 
deficits in protein quality control, but rather to the impaired degradation capacity. In line with 
the study by Zhang et al., CVB3 infection caused the fourfold mRNA induction of the 
proapoptotic transcription factor CHOP, which is involved in the unfolded protein response 
(143). However, other UPR-related genes, such as ATF6, IRE1, or XBP1 were not regulated 
during acute myocardits (see Fig. 28). Only the sterol regulatory element-binding protein-1 
(SREBP1) was slightly induced in β5i/LMP7-/- but not in C57BL/6 mice at d8 p.i. These 
findings indicate that CVB3 infection activates the UPR, but that increased cytosolic protein 
aggregation does not induce a differential regulation of ER-associated stress responsive genes 
in β5i/LMP7-/- hearts.  
Macrophages that represent the major fraction of invading inflammatory cells in CVB3 
myocarditis (see Fig. 6) generate ROS (167) and thus create a highly reactive, pro-apoptotic 
environment (158) even for IP-competent cells. However, despite the presence of 
inflammatory lesions, no apoptosis was detectable within cellular infiltrates and 
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cardiomyocytes of IP-competent C57BL/6 hearts. Therefore, the question was raised whether 
IP-formation affects protection mechanisms against cytokine- and ROS-induced apoptosis. 
The complex of the transcription factor Nfr2 (nuclear factor erythroid 2-related factor 2) and 
its inhibitor Keap1 (kelch-like ECH-associated protein 1) is a cellular sensor of oxidative 
stress that controls the coordinated expression of antioxidant genes. Furthermore, Nrf2 
activity increases the expression of the antiapoptotic protein Bcl-2 (B-cell lymphoma 2) (168) 
and regulates the sensitivity to Fas-mediated apoptosis in T cells (169). Keap1, which tethers 
Nrf2 in the cytoplasm, serves as an adaptor for the cullin 3/ring box 1 (Cul3/Rbx1) E3 
ubiquitin ligase complex. Under normal cellular conditions, the Keap1/Cul3/Rbx1 complex 
constantly mediates the degradion of Nrf2 by the proteasome. Oxidative stress induces the 
stabilization of Nrf2 and its translocation to the nucleus, where it binds to cis-acting 
antioxidant-response elements (ARE) in the promotor region of cytoprotective genes (170). A 
recent study by Pickering et al. highlights the role of the Nrf2 signal transduction pathway in 
the transient adaptation of the protasome capacity to degrade oxidized proteins. Although 
concentrating on 20S proteasomes instead of physiological 26S proteasomes, they found an 
increase of β1, β1i/LMP2 and PA28αβ protein levels in murine embryonal fibroblasts upon 
H2O2 treatment, which was abrogated by Nrf2-siRNA treatment in case of β1 and PA28αβ 
(171). Interestingly, ARE consensus sequences are present upstream of standard 20S subunits 
(β1, β2, β6, α1-3) and in the promotor region of β5i/LMP7, whereas they are absent in 
β1i/LMP2 and β2i/MECL-1 (171). In viral myocarditis, the cardiac expression of Nrf2 was 
upregulated two- to threefold in IP-competent C57BL/6 mice upon CVB3 infection, whereas 
the mRNA expression levels did not change in β5i/LMP7-/- hearts (see Fig. 28). Notably, 
baseline expression of Nrf2 did not differ between non-infected C57BL/6 respectively 
β5i/LMP7-/- hearts. Cardiac mRNA expression levels of important antioxidant enzymes, such 
as glutathione peroxidase, catalase, or superoxide dismutase were found to be in the same 
range in both, infected and non-infected C57BL/6 and β5i/LMP7-/- hearts. However, the 
induction of Gclc (glutamate-cysteine ligase, catalytic subunit) and Nqo1 (NAD(P)H quinone 
oxidoreductase 1) mRNA expression was  increased in C57BL/6 (see Fig. 28) but not in 
β5i/LMP7-/- hearts. Both, Nqo1 and Gclc are Nrf2-driven cytoprotective mediators (172). 
These findings imply a defective stress-induced apoptosis regulation in β5i/LMP7-/-  mice. 
Nonetheless, the mechanistic link of IP-formation to Nrf2 expression levels remains unclear 
and could be an aspect of further investigation. 
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6.3.3 IPs are involved in NF-κB cell signaling in a tissue or disease-specific 
manner 
Given that viral replication and the early induction of inflammatory cytokines were identical 
in both hosts, it was of considerable interest to examine the increased immune cell recruitment 
to β5i/LMP7-deficient hearts. One regulator of highest impact is the transcription factor NF-
κB, owing to its central role in immunological processes and the vast range of genes that it 
controls. In resting cells, inactive NF-κB dimers are sequestered in the cytoplasm by the 
association to I-κB family members (173). Activation of NF-κB requires phosphorylation and 
K48-linked poly-ubiquitylation of I-κB and subsequent proteasomal degradation. This 
unmasks a nuclear targeting sequence of NF-κB and promotes the translocation of NF-κB to 
the nucleus (174) where it regulates gene transcription.  
Turnover of I-κB was recently shown to be accelerated in cells expressing IPs compared to 
cells predominantly expressing standard or mixed proteasomes (127;162;175). This 
emphasizes the particular role of IPs in cell signaling, demonstrating that the enhanced 
degradation capacity of IPs is not limited to poly-Ub, oxidatively damaged proteins, but also 
affects the functionality of cellular substrates such as NF-κB. The present work demonstrates 
significantly reduced levels of NF-κB p50 subunits in IP-deficient cardiomyocytes and 
inflammatory cells (see Fig. 24). This reflects limited proteasomal degradation of NF-κB 
p105 precursor proteins upon exposure to cytokines, potentially influencing signal 
transduction. 
Among others, NF-κB acts on the transcription of numerous genes for pro-inflammatory 
cytokines, chemokines and immune receptors. Besides, NF-κB mediates gene expression of 
superoxide dismutase and thioredoxin, which provide cellular protection to oxidative stress 
(176-178). Gene products that are regulated by NF-κB such as interleukin-1β and TNF-α can 
in turn activate NF-κB in a positive regulatory loop, which boosts inflammatory responses 
(179). Therefore, constitutive activation of NF-κB pathways is linked to inflammatory 
diseases like multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and asthma 
(179;180). Targeting the proteasome activity recently led to success in various murine models 
of autoimmune disorders. Block of NF-κB activity by the proteasome inhibitor bortezomib 
ameliorates glomerulonephritis and prolongs survival of mice with lupus-like disease (181). 
Both, partial inhibition of proteasomes by bortezomib and the specific deletion of β5i/LMP7 
substantially attenuate inflammation in experimental colitis. This was also ascribed to 
impaired NF-κB signaling, limiting secretion of pro-inflammatory cyto- and chemokines 
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(182). In a mouse model of rheumatoid arthritis, inhibition of β5i/LMP7 by the selective 
epoxyketone inhibitor PR-957 (183) hampers the production of IL-23, IL-2, IL-6, TNF-α and 
IFN-γ and consequently attenuates disease progression (184). However, in a reporter cell line, 
PR-957 does not inhibit NF-κB activity, indicating that IPs may regulate cytokine expression 
also via NF-κB–independent pathways (185). In the present model, cytokine induction in IP-
deficient hearts was comparable to that in C57BL/6 mice upon CVB3 infection (see Fig. 20). 
Also serum levels of the selected chemokines RANTES, IP-10, and MCP-1 were observed to 
be within the same range (see Fig. 21).  
Given that cytokine stimulation resulted in impaired NF-κB -activation in β5i/LMP7-/- cells in 
vitro, it was of interest to investigate whether IP-deficiency affected NF-kB signaling in vivo. 
One indicator for impaired NF-κB signaling in β5i/LMP7-/- mice is a member of the pentaxin 
superfamily, Ptx3. The promotor region of pentaxin 3 contains a NF-κB-binding element, 
which is operative in the response to inflammatory cytokines TNF-α and/or IL-1β (186). Ptx3 
belongs to the family of pattern-recognition receptors (PRRs) (187), which are able to detect 
highly conserved molecular motifs shared by a large group of microorgansims (pathogen-
associated molecular patterns=PAMPs) (188). Expressed e.g. by endothelial cells, 
monocytes/macrophages and fibroblasts, Ptx3 opsonizes various pathogens or pathogen-
derived patterns, including human and murine cytomegalovirus (CMV) or H3N2 influenza 
virus (186). As reviewed by Kunes et al., Ptx3 plays an important role in dampening an 
inappropriate, exaggerated inflammatory response to acute infections and cardiovascular 
diseases such myocardial infarction and ischemia/reperfusion injury (186). In murine CVB3 
myocarditis, Ptx3 was massively up-regulated in IP-competent C57BL/6, but not in IP-
deficient hearts (see Fig. 28). One may speculate, that the early cytokine response (e.g. TNF-
α, Fig. 20) activated Ptx3 via a NF-κB -dependent pathway that was delayed in β5i/LMP7-/- 
mice, thereby protecting IP-competent mice from excessive inflammation. Therefore, this 
aspect of PAMP-associated cell signaling upon CVB3-infection could be a worthwhile 
objective of further investigation.  
Besides, apoptotic cell death of invading inflammatory cells and adjacent cardiomyocytes as 
observed in IP-deficient mice (see Fig. 27) may actually cause an increased release of 
damage-associated molecular patterns (DAMPs). DAMPs mediate tissue repair and signal the 
threat of infection and cellular injury to the organism (189;190). It is known, that different 
Toll-like receptors (TLRs) are activated by the recognition of PAMPs and DAMPs (189). In 
consequence, the downstream induction of transcription factors regulates the expression of 
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specific genes that modulate the inflammatory response. Notably, DAMPs have been 
implicated in several pathologies where prolonged inflammation plays a role. This led to the 
hypothesis, that TLR activation by DAMPs elicits positive feedback loops, resulting in 
proliferation of pro-inflammatory responses and inflammation (189). Apart from Ptx3 
signaling, this can also explain the exacerbation of acute inflammation and killing of non-
infected cardiomyocytes in IP-deficient animals.  
Together, the present findings emphasize the potential implication of IPs in various signal 
transduction pathways in a tissue or disease-specific manner.  
6.4 Conclusion: IPs exert protective functions in the pathogenesis 
of CVB3 myocarditis  
Expression of IPs as a physiological response to a great variety of stressors modifies the full 
range of cellular functions in which standard proteasomes are already involved. Based on the 
underlying disease, IPs may either exert protective effects or they aggravate the consequences 
of inflammation in a tissue-specific manner. In viral heart disease, intact IP-formation 
preserves protein homeostasis by the accelerated degradation of oxidatively damaged, poly-
Ub proteins and the prevention of apoptotic cell death (see Fig. 29).  
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Fig. 29 Working model. Cardiac IP formation protects from apoptotic cell death by the preservation of 
protein homeostasis. 1: During regular cell metabolims, the proteasome degrades proteins such as I-κB, which 
are involved e.g. in cell signaling, gene transcription, or differentiation. Antigen presentation from abberant gene 
products (predominantly DRiPs) contributes to immune surveillance by CD8+ T cells via MHC class I 
presentation. 2: CVB3 infection represents a massive threat to cellular proteostastis. 3: It triggers an IFN-
response and the generation of reactive oxygen species which 4: affect cellular proteins, especially the nascent 
pool of proteins 5: The standard proteasome is less efficient than the IP in eliminating oxidant-damaged and 
poly-ubiquitylated proteins resulting in the persistent aggregation of ALIS. Delayed degradation of regulatory 
proteins such as I-κB impairs NF-κB activation and may contribute to apoptotic cell death in IP-deficient, CVB3 
challenged inflammatory cells and cardiomyocytes. 6: The formation of IPs preserves protein homeostasis due to 
accelerated degradation of transiently accumulated ALIS, which sequester toxic abberant proteins as well as viral 
proteins. 
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SD standard deviation 
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ss single strand 
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TEAD triethylammonium acetate 
TNF-α tumor necrosis factor α 
TAP Transporter associated with antigen processing 
TUNEL terminal deoxynucleotidyl transferase dUTP nick 
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TLR Toll-like receptor 
TEMED tetramethylethylenediamine 
U units 
Ub ubiquitin 
UBE2L6 ubiquitin/ISG15-conjugating enzyme E2 L6 
UTR untranslated region 
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UPR unfolded protein response 
XBP1 X-box binding protein 1 
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